<div id="page0" style="width:595.3pt;height:793.7pt">
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,700.6667,102)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABwAAAAcCAYAAAByDd+UAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAlElEQVR4nO3NwQqCQABF0ff/vxQMlgyGIcYwiBmGIVkyMJALI8Fe
PxFv1YWzvqA4/Ic/H37WlUp4LwuVML9mKmGanlRCjJFKCCFQCY/xTiUMw41K6Pue
SuiuHZXQXloqoTk3VEJ9qqkEX1VUgvOeSjg6RyUUZUklHIqCStjnOZVgs4xKSK2l
EpJdSiWYZEslbIyh0hcZiRZGb9cznQAAAABJRU5ErkJggg==">
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>
<p style="top:741.9pt;left:294.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">1</span></b></p>
<p style="top:35.8pt;left:476.0pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">SyStematic Review</span></b></p>
<p style="top:43.9pt;left:465.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">published: 15 January 2018</span></p>
<p style="top:51.9pt;left:455.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">doi: 10.3389/fneur.2017.00744</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:336.6pt;left:125.3pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">Edited by: </span></i></b></p>
<p style="top:346.6pt;left:102.9pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Stefania Mondello,  </span></i></p>
<p style="top:356.6pt;left:79.4pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">University of Messina, Italy</span></i></p>
<p style="top:370.9pt;left:114.4pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">Reviewed by: </span></i></b></p>
<p style="top:380.9pt;left:109.6pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Mikulas Chavko,  </span></i></p>
<p style="top:390.9pt;left:62.8pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Naval Medical Research Center, </span></i></p>
<p style="top:400.9pt;left:117.9pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">United States  </span></i></p>
<p style="top:410.9pt;left:108.2pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Eric Peter Thelin, </span></i></p>
<p style="top:420.9pt;left:84.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">University of Cambridge,  </span></i></p>
<p style="top:430.9pt;left:109.9pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">United Kingdom</span></i></p>
<p style="top:445.2pt;left:98.3pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">*Correspondence:</span></i></b></p>
<p style="top:455.2pt;left:97.8pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Luis Teodoro da Luz  </span></i></p>
<p style="top:465.2pt;left:81.4pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">luis.daluz@sunnybrook.ca</span></i></p>
<p style="top:488.9pt;left:99.9pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">Specialty section: </span></i></b></p>
<p style="top:498.9pt;left:80.6pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">This article was submitted  </span></i></p>
<p style="top:508.9pt;left:109.3pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">to Neurotrauma,  </span></i></p>
<p style="top:518.9pt;left:90.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">a section of the journal </span></i></p>
<p style="top:528.9pt;left:92.9pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Frontiers in Neurology</span></i></p>
<p style="top:543.2pt;left:72.2pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">Received:</span></i></b><i><span style="font-family:Arial,serif;font-size:7.0pt"> 24&#xa0;October&#xa0;2017</span></i></p>
<p style="top:553.2pt;left:64.5pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">Accepted:</span></i></b><i><span style="font-family:Arial,serif;font-size:7.0pt"> 22&#xa0;December&#xa0;2017</span></i></p>
<p style="top:563.2pt;left:70.7pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">Published:</span></i></b><i><span style="font-family:Arial,serif;font-size:7.0pt"> 15&#xa0;January&#xa0;2018</span></i></p>
<p style="top:577.4pt;left:130.4pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">Citation: </span></i></b></p>
<p style="top:587.5pt;left:57.2pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Bhatti&#xa0;J, Nascimento&#xa0;B, Akhtar&#xa0;U, </span></i></p>
<p style="top:597.5pt;left:57.8pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Rhind&#xa0;SG, Tien&#xa0;H, Nathens&#xa0;A and </span></i></p>
<p style="top:607.5pt;left:49.8pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">da&#xa0;Luz&#xa0;LT (2018) Systematic Review </span></i></p>
<p style="top:617.5pt;left:69.2pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">of Human and Animal Studies </span></i></p>
<p style="top:627.5pt;left:49.8pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Examining the Efficacy and Safety of </span></i></p>
<p style="top:637.5pt;left:75.1pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">N-Acetylcysteine (NAC) and </span></i></p>
<p style="top:647.5pt;left:55.9pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">N-Acetylcysteine Amide (NACA) in </span></i></p>
<p style="top:657.5pt;left:69.4pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Traumatic Brain Injury: Impact  </span></i></p>
<p style="top:667.5pt;left:71.9pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">on Neurofunctional Outcome  </span></i></p>
<p style="top:677.5pt;left:74.2pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">and Biomarkers of Oxidative  </span></i></p>
<p style="top:687.5pt;left:84.1pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Stress and Inflammation. </span></i></p>
<p style="top:697.5pt;left:96.1pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Front. Neurol. 8:744.  </span></i></p>
<p style="top:707.5pt;left:64.6pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">doi: 10.3389/fneur.2017.00744</span></i></p>
<p style="top:130.9pt;left:175.7pt;line-height:21.0pt"><b><span style="font-family:Arial,serif;font-size:21.0pt">Systematic Review of Human and </span></b></p>
<p style="top:153.8pt;left:175.7pt;line-height:21.0pt"><b><span style="font-family:Arial,serif;font-size:21.0pt">animal Studies examining the </span></b></p>
<p style="top:176.8pt;left:175.7pt;line-height:21.0pt"><b><span style="font-family:Arial,serif;font-size:21.0pt">efficacy and Safety of </span></b></p>
<p style="top:199.8pt;left:175.7pt;line-height:21.0pt"><b><i><span style="font-family:Arial,serif;font-size:21.0pt">N-</span></i></b><b><span style="font-family:Arial,serif;font-size:21.0pt">acetylcysteine (Nac) and </span></b></p>
<p style="top:222.8pt;left:175.7pt;line-height:21.0pt"><b><i><span style="font-family:Arial,serif;font-size:21.0pt">N-</span></i></b><b><span style="font-family:Arial,serif;font-size:21.0pt">acetylcysteine amide (Naca) in </span></b></p>
<p style="top:245.8pt;left:175.7pt;line-height:21.0pt"><b><span style="font-family:Arial,serif;font-size:21.0pt">traumatic Brain injury: impact on </span></b></p>
<p style="top:268.8pt;left:175.7pt;line-height:21.0pt"><b><span style="font-family:Arial,serif;font-size:21.0pt">Neurofunctional Outcome and </span></b></p>
<p style="top:291.8pt;left:175.7pt;line-height:21.0pt"><b><span style="font-family:Arial,serif;font-size:21.0pt">Biomarkers of Oxidative Stress and </span></b></p>
<p style="top:314.8pt;left:175.7pt;line-height:21.0pt"><b><span style="font-family:Arial,serif;font-size:21.0pt">inflammation</span></b></p>
<p style="top:350.1pt;left:175.7pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Junaid Bhatti</span></i><sup><i><span style="font-family:Arial,serif;font-size:5.2pt">1</span></i></sup><i><span style="font-family:Arial,serif;font-size:9.0pt">, Barto Nascimento</span></i><sup><i><span style="font-family:Arial,serif;font-size:5.2pt">1</span></i></sup><i><span style="font-family:Arial,serif;font-size:9.0pt">, Umbreen Akhtar</span></i><i><span style="font-family:Arial,serif;font-size:5.2pt"> </span></i><sup><i><span style="font-family:Arial,serif;font-size:5.2pt">2</span></i></sup><i><span style="font-family:Arial,serif;font-size:9.0pt">, Shawn G. Rhind</span></i><sup><i><span style="font-family:Arial,serif;font-size:5.2pt">3</span></i></sup><i><span style="font-family:Arial,serif;font-size:9.0pt">, Homer Tien</span></i><sup><i><span style="font-family:Arial,serif;font-size:5.2pt">1</span></i></sup><i><span style="font-family:Arial,serif;font-size:9.0pt">, </span></i></p>
<p style="top:361.6pt;left:175.7pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Avery Nathens</span></i><sup><i><span style="font-family:Arial,serif;font-size:5.2pt">1</span></i></sup><i><span style="font-family:Arial,serif;font-size:9.0pt"> and Luis Teodoro da Luz</span></i><sup><i><span style="font-family:Arial,serif;font-size:5.2pt">1</span></i></sup><i><span style="font-family:Arial,serif;font-size:9.0pt">*</span></i></p>
<p style="top:381.7pt;left:175.7pt;line-height:4.1pt"><i><span style="font-family:Arial,serif;font-size:4.1pt">1</span></i><i><span style="font-family:Arial,serif;font-size:7.0pt"> Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, </span></i></p>
<p style="top:391.7pt;left:175.7pt;line-height:4.1pt"><i><span style="font-family:Arial,serif;font-size:4.1pt">2</span></i><i><span style="font-family:Arial,serif;font-size:7.0pt"> Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, </span></i><i><span style="font-family:Arial,serif;font-size:4.1pt">3</span></i><i><span style="font-family:Arial,serif;font-size:7.0pt"> Defense Research and Development </span></i></p>
<p style="top:401.7pt;left:175.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">Canada (DRDC), Toronto Research Centre, Toronto, ON, Canada</span></i></p>
<p style="top:427.5pt;left:175.7pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt">Background:</span></b><span style="font-family:Arial,serif;font-size:10.0pt"> No new therapies for traumatic brain injury (TBI) have been officially </span></p>
<p style="top:441.5pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">translated into current practice. At the tissue and cellular level, both inflammatory and </span></p>
<p style="top:455.5pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">oxidative processes may be exacerbated post-injury and contribute to further brain </span></p>
<p style="top:469.5pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">damage. </span><i><span style="font-family:Arial,serif;font-size:10.0pt">N-</span></i><span style="font-family:Arial,serif;font-size:10.0pt">acetylcysteine (NAC) has the potential to downregulate both processes. </span></p>
<p style="top:483.5pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">This review focuses on the potential neuroprotective utility of NAC and </span><i><span style="font-family:Arial,serif;font-size:10.0pt">N</span></i><span style="font-family:Arial,serif;font-size:10.0pt">-acetylcysteine </span></p>
<p style="top:497.5pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">amide (NACA) post-TBI.</span></p>
<p style="top:517.3pt;left:175.7pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt">methods:</span></b><span style="font-family:Arial,serif;font-size:10.0pt"> Medline, Embase, Cochrane Library, and ClinicalTrials.gov were searched up </span></p>
<p style="top:531.3pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">to July 2017. Studies that examined clinical and laboratory effects of NAC and NACA </span></p>
<p style="top:545.3pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">post-TBI in human and animal studies were included. Risk of bias was assessed in </span></p>
<p style="top:559.3pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">human and animal studies according to the design of each study (randomized or not). </span></p>
<p style="top:573.3pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">The primary outcome assessed was the effect of NAC/NACA treatment on functional </span></p>
<p style="top:587.3pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">outcome, while secondary outcomes included the impact on biomarkers of inflammation </span></p>
<p style="top:601.3pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">and oxidation. Due to the clinical and methodological heterogeneity observed across </span></p>
<p style="top:615.3pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">studies, no meta-analyses were conducted.</span></p>
<p style="top:635.0pt;left:175.7pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt">Results:</span></b><span style="font-family:Arial,serif;font-size:10.0pt"> Our analyses revealed only three human trials, including two randomized con-</span></p>
<p style="top:649.0pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">trolled trials (RCTs) and 20 animal studies conducted using standardized animal models </span></p>
<p style="top:663.0pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">of brain injury. The two RCTs reported improvement in the functional outcome post-</span></p>
<p style="top:677.0pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">NAC/NACA administration. Overall, the evidence from animal studies is more robust and </span></p>
<p style="top:691.0pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">demonstrated substantial improvement of cognition and psychomotor performance fol-</span></p>
<p style="top:705.0pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">lowing NAC/NACA use. Animal studies also reported significantly more cortical sparing, </span></p>


<p style="top:741.9pt;left:294.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">2</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>
<p style="top:61.1pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">reduced apoptosis, and lower levels of biomarkers of inflammation and oxidative stress. </span></p>
<p style="top:75.1pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">No safety concerns were reported in any of the studies included in this analysis.</span></p>
<p style="top:94.8pt;left:175.7pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt">conclusion:</span></b><span style="font-family:Arial,serif;font-size:10.0pt"> Evidence from the animal literature demonstrates a robust association for </span></p>
<p style="top:108.8pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">the prophylactic application of NAC and NACA post-TBI with improved neurofunctional </span></p>
<p style="top:122.8pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">outcomes and downregulation of inflammatory and oxidative stress markers at the tissue </span></p>
<p style="top:136.8pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">level. While a growing body of scientific literature suggests putative beneficial effects of </span></p>
<p style="top:150.8pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">NAC/NACA treatment for TBI, the lack of well-designed and controlled clinical investiga-</span></p>
<p style="top:164.8pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">tions, evaluating therapeutic outcomes, prognostic biomarkers, and safety profiles, limits </span></p>
<p style="top:178.8pt;left:175.7pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">definitive interpretation and recommendations for its application in humans at this time.</span></p>
<p style="top:200.2pt;left:175.7pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Keywords: </span></b><b><i><span style="font-family:Arial,serif;font-size:7.0pt">N-</span></i></b><b><span style="font-family:Arial,serif;font-size:7.0pt">acetylcysteine, </span></b><b><i><span style="font-family:Arial,serif;font-size:7.0pt">N-</span></i></b><b><span style="font-family:Arial,serif;font-size:7.0pt">acetylcysteine amide, traumatic brain injury, neurofunctional outcome, animal </span></b></p>
<p style="top:209.7pt;left:175.7pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">models, oxidative stress, inflammation modulation</span></b></p>
<p style="top:234.9pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">iNtRODUctiON</span></b></p>
<p style="top:256.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Traumatic brain injury (TBI) is a leading cause of death and </span></p>
<p style="top:268.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">disability in the United States and globally (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">1</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">2</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). In the USA, </span></p>
<p style="top:279.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">TBI results in more than 250,000 hospitalizations and 2.5 mil-</span></p>
<p style="top:291.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">lion hospital visits (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">3</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), and the costs of immediate TBI care is </span></p>
<p style="top:302.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">estimated to be up to 100 billion US$ (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">4</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Moreover, the burden </span></p>
<p style="top:314.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">caused by the consequent degree of disability that TBI patients </span></p>
<p style="top:325.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">suffer is estimated to be $2.5&#x2013;$6.5 million (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">5</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). These disabilities </span></p>
<p style="top:337.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">include, but are not limited to, severe motor and cognitive impair-</span></p>
<p style="top:348.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ments and mental health problems, such as addiction and mood </span></p>
<p style="top:360.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">disorders (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">6</span><span style="font-family:MinionPro,serif;font-size:9.5pt">).</span></p>
<p style="top:371.9pt;left:56.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">At the brain tissue level, the damage from the primary insult </span></p>
<p style="top:383.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">is mostly irreparable (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">7</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">8</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Additionally, the initial tissue dam-</span></p>
<p style="top:394.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">age may be worsened by a complex secondary injury process </span></p>
<p style="top:406.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">following the primary insult (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">9</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). These processes consist of a </span></p>
<p style="top:417.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cascade of metabolic, cellular, and molecular events related to </span></p>
<p style="top:429.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">extensive tissue destruction and repair (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">10</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). These mechanisms </span></p>
<p style="top:440.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">are represented by the imbalance of glucose demand and supply, </span></p>
<p style="top:452.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">disruption of calcium homeostasis, increased formation of free </span></p>
<p style="top:463.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">radicals, lipid peroxidation, mitochondrial dysfunction, and local </span></p>
<p style="top:475.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">release of catecholamines (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">11</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">13</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). It has been shown that these </span></p>
<p style="top:487.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">processes, or lack thereof, result in further damage to the already </span></p>
<p style="top:498.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">critically injured brain tissue (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">9</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">14</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Local consequences of this </span></p>
<p style="top:510.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">intricate process include vasoconstriction and formation of </span></p>
<p style="top:521.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">microthrombi in the microvasculature, with further ischemia and </span></p>
<p style="top:533.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">edema (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">15</span><span style="font-family:MinionPro,serif;font-size:9.5pt">); initiation and exacerbation of peripheral and central </span></p>
<p style="top:544.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">inflammatory process with release of pro- and anti-inflammatory </span></p>
<p style="top:556.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mediators (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">16</span><span style="font-family:MinionPro,serif;font-size:9.5pt">); a subsequent rise of intracranial pressure (ICP) </span></p>
<p style="top:567.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">with unfavorable neurological outcome or death (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">17</span><span style="font-family:MinionPro,serif;font-size:9.5pt">).</span></p>
<p style="top:579.0pt;left:56.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Part of this process, involving disruption of the capacity </span></p>
<p style="top:590.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of mitochondria to scavenge free radicals or reactive oxygen </span></p>
<p style="top:602.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">species (ROS), is of particular interest in this review (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">18</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). The </span></p>
<p style="top:613.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">level of glutathione, a naturally available antioxidant within </span></p>
<p style="top:625.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">the mitochondria, decreases rapidly after brain tissue injury </span></p>
<p style="top:636.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">19</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), which leads to accumulation of cytotoxic ROS. </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">N-</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">acetyl </span></p>
<p style="top:648.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">l-cysteine (NAC), a thiol containing l-amino acid, replenishes </span></p>
<p style="top:659.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">glutathione synthesis (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), and thereby may ameliorate secondary </span></p>
<p style="top:671.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">brain injury (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) as it counters the deleterious effects oxidative </span></p>
<p style="top:682.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">stress, promotes redox-regulated cell signaling, and dampens </span></p>
<p style="top:694.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">excessive immuno-inflammatory responses (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">21</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). NAC has been </span></p>
<p style="top:705.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">an FDA approved drug since 1985 (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">22</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) and has been used for </span></p>
<p style="top:235.4pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">management of acetaminophen toxicity (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">23</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Additionally, a few </span></p>
<p style="top:246.9pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">clinical trials have evaluated NAC targeting neurological diseases, </span></p>
<p style="top:258.4pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">including autism (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">24</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), major depression and other psychiatry </span></p>
<p style="top:269.9pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">conditions (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">9</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">25</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">26</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), neonatal asphyxia (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">27</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), and neurodegen-</span></p>
<p style="top:281.4pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">erative disease (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">28</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Furthermore, recent studies have shown that </span></p>
<p style="top:292.9pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">NAC can reduce levels of oxidative-stress biomarkers following </span></p>
<p style="top:304.4pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">surgical trauma, such as in abdominal aortic aneurysm repair and </span></p>
<p style="top:315.9pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">surgical repair of atrial fibrillation (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">29</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">30</span><span style="font-family:MinionPro,serif;font-size:9.5pt">).</span></p>
<p style="top:327.4pt;left:317.7pt;line-height:9.5pt"><i><span style="font-family:MinionPro,serif;font-size:9.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">-Acetylcysteine is relatively safe to administer, has mild side </span></p>
<p style="top:338.9pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">effects such as nausea, vomiting, rash, and fever, and rarely results </span></p>
<p style="top:350.4pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in anaphylaxis (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">23</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). However, a limitation of using NAC is that </span></p>
<p style="top:361.9pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">it has a low blood&#x2013;brain barrier (BBB) permeability (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). More </span></p>
<p style="top:373.4pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">recently, an amide derivate of NAC known as </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">-acetylcysteine </span></p>
<p style="top:384.9pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">amide (NACA) was developed with a higher BBB permeability </span></p>
<p style="top:396.4pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">than NAC resulting in increased central nervous system bioavail-</span></p>
<p style="top:407.9pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ability (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">31</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). However, this new derivate has never been used in </span></p>
<p style="top:419.4pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">studies conducted in humans (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">32</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Both NAC and NACA have </span></p>
<p style="top:430.9pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">not been approved for use in TBI by the FDA or Health Canada.</span></p>
<p style="top:442.5pt;left:317.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Given the lack of therapies shown to improve outcome fol-</span></p>
<p style="top:454.0pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">lowing TBI, we sought to survey the current literature on the </span></p>
<p style="top:465.5pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">underlying the biological and clinical effects of NAC and/or </span></p>
<p style="top:477.0pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">NACA, with respect to their ability to improve neurofunctional </span></p>
<p style="top:488.5pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">outcome, </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">via</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt"> modulation of oxidative stress pathways, inflam-</span></p>
<p style="top:500.0pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">matory responses, and cell death signaling in both humans and </span></p>
<p style="top:511.5pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">animals sustaining brain trauma.</span></p>
<p style="top:535.0pt;left:306.2pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">metHODS</span></b></p>
<p style="top:557.0pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">This systematic review was reported in accordance with the </span></p>
<p style="top:568.5pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Preferred Reporting Items for Systematic Reviews and Meta-</span></p>
<p style="top:580.0pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Analyses (PRISMA) guidelines (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">33</span><span style="font-family:MinionPro,serif;font-size:9.5pt">).</span></p>
<p style="top:600.0pt;left:306.2pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Search methods</span></b></p>
<p style="top:613.5pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">MEDLINE (1946&#x2013;Nov 2017), EMBASE (1947&#x2013;Nov 2017), </span></p>
<p style="top:625.0pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Cochrane Controlled Trials Register, and Cochrane Database of </span></p>
<p style="top:636.5pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Systematic Reviews (from inception to July 2017) were searched. </span></p>
<p style="top:648.0pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The search was not restricted by date and language. Search terms </span></p>
<p style="top:659.5pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">were defined </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">a&#xa0; priori</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt"> and by reviewing the MeSH (Medical </span></p>
<p style="top:671.0pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Subject Headings) terms of articles identified in preliminary </span></p>
<p style="top:682.6pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">literature searches. The search strategy was based on the initial </span></p>
<p style="top:694.1pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Medline search strategy and was modified as necessary for the </span></p>
<p style="top:705.6pt;left:306.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">other databases. We used a sensitive search strategy combining </span></p>


<p style="top:707.3pt;left:327.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">taBle 1</span></b><span style="font-family:Arial,serif;font-size:7.0pt"> | Characteristics of human studies.</span></p>
<p style="top:707.3pt;left:343.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Reference</span></b></p>
<p style="top:664.3pt;left:343.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Population, mean/</span></b></p>
<p style="top:664.3pt;left:353.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">median age</span></b></p>
<p style="top:595.2pt;left:343.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Sample </span></b></p>
<p style="top:595.2pt;left:353.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">size, % </span></b></p>
<p style="top:595.2pt;left:362.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">male</span></b></p>
<p style="top:561.9pt;left:343.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">injury </span></b></p>
<p style="top:561.9pt;left:353.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">type</span></b></p>
<p style="top:521.7pt;left:343.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">control</span></b></p>
<p style="top:486.7pt;left:343.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Nac(a) dose </span></b></p>
<p style="top:436.0pt;left:343.9pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">Via</span></i></b></p>
<p style="top:414.2pt;left:343.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">First </span></b></p>
<p style="top:414.2pt;left:353.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">dose</span></b></p>
<p style="top:389.1pt;left:343.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Other doses</span></b></p>
<p style="top:298.9pt;left:343.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">length of </span></b></p>
<p style="top:298.9pt;left:353.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">follow-up</span></b></p>
<p style="top:250.8pt;left:343.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Outcome(s) measured</span></b></p>
<p style="top:160.2pt;left:343.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Findings</span></b></p>
<p style="top:707.3pt;left:380.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Amen et&#xa0;al. </span></p>
<p style="top:707.3pt;left:389.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">34</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:664.3pt;left:380.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Retired NFL players, </span></p>
<p style="top:664.3pt;left:389.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">age: NR</span></p>
<p style="top:595.2pt;left:379.9pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">N</span></i><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">=</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;30, </span></p>
<p style="top:595.2pt;left:389.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">100%</span></p>
<p style="top:561.9pt;left:380.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Repeated </span></p>
<p style="top:561.9pt;left:389.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">mild TBI</span></p>
<p style="top:521.6pt;left:380.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Self-</span></p>
<p style="top:521.6pt;left:389.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">matched</span></p>
<p style="top:486.7pt;left:380.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Diet with NAC</span></p>
<p style="top:436.0pt;left:380.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Oral</span></p>
<p style="top:414.2pt;left:380.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NR</span></p>
<p style="top:389.1pt;left:380.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Diet supplement, dose NR</span></p>
<p style="top:298.9pt;left:380.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2&#x2013;12&#xa0;months</span></p>
<p style="top:250.8pt;left:380.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Microcognitive test, SPECT </span></p>
<p style="top:250.8pt;left:389.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">image analysis</span></p>
<p style="top:160.2pt;left:380.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 Improvement of general </span></p>
<p style="top:153.2pt;left:389.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">cognition</span></p>
<p style="top:160.2pt;left:399.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 Improvements in brain perfusion</span></p>
<p style="top:707.3pt;left:412.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Hoffer et&#xa0;al. </span></p>
<p style="top:707.3pt;left:422.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">35</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:664.3pt;left:412.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Military personnel, </span></p>
<p style="top:664.3pt;left:422.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">median age: </span></p>
<p style="top:664.3pt;left:431.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">22&#xa0;years</span></p>
<p style="top:595.2pt;left:412.2pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">N</span></i><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">=</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;81, </span></p>
<p style="top:595.2pt;left:422.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">99%</span></p>
<p style="top:561.9pt;left:412.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Mild post </span></p>
<p style="top:561.9pt;left:422.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">blast injury</span></p>
<p style="top:521.6pt;left:412.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Placebo</span></p>
<p style="top:486.7pt;left:412.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">4&#xa0;g loading </span></p>
<p style="top:486.7pt;left:422.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">dose</span></p>
<p style="top:436.0pt;left:412.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Oral</span></p>
<p style="top:414.1pt;left:412.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Up to </span></p>
<p style="top:414.1pt;left:422.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">72&#xa0;h</span></p>
<p style="top:389.1pt;left:412.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">4&#xa0;g/day for 4&#xa0;days followed </span></p>
<p style="top:389.1pt;left:422.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">by 3&#xa0;g/day for 3&#xa0;days</span></p>
<p style="top:298.9pt;left:412.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">7&#xa0;days</span></p>
<p style="top:250.7pt;left:412.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Hearing loss, headache, </span></p>
<p style="top:250.7pt;left:422.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">confusion, memory, sleep </span></p>
<p style="top:250.7pt;left:431.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">and balance problems, </span></p>
<p style="top:250.7pt;left:441.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">COWA, animal naming</span></p>
<p style="top:160.2pt;left:412.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 Improvement in cognition and </span></p>
<p style="top:153.2pt;left:422.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">balance</span></p>
<p style="top:160.2pt;left:431.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 Significant resolution of </span></p>
<p style="top:153.2pt;left:441.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">symptoms</span></p>
<p style="top:707.3pt;left:454.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Clark et&#xa0;al. </span></p>
<p style="top:707.3pt;left:464.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">36</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:664.3pt;left:454.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Children, mean age: </span></p>
<p style="top:664.3pt;left:464.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">9&#xa0;years</span></p>
<p style="top:595.2pt;left:454.3pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">N</span></i><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">=</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;14, </span></p>
<p style="top:595.2pt;left:464.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">60%</span></p>
<p style="top:561.8pt;left:454.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Severe, </span></p>
<p style="top:561.8pt;left:463.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">GCS&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">&#x2264;</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;8</span></p>
<p style="top:521.6pt;left:454.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Placebo</span></p>
<p style="top:486.7pt;left:454.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 140&#xa0;mg/</span></p>
<p style="top:486.7pt;left:464.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">kg/dose and </span></p>
<p style="top:486.7pt;left:473.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">probenecid </span></p>
<p style="top:486.7pt;left:483.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">25&#xa0;mg/kg/</span></p>
<p style="top:486.7pt;left:492.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">dose</span></p>
<p style="top:436.0pt;left:454.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NG </span></p>
<p style="top:436.0pt;left:464.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">tube</span></p>
<p style="top:414.1pt;left:454.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NR</span></p>
<p style="top:389.1pt;left:454.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 70&#xa0;mg/kg/dose, 17 </span></p>
<p style="top:389.1pt;left:464.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">doses over 3&#xa0;days and </span></p>
<p style="top:389.1pt;left:473.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">probenecid 10&#xa0;mg/kg 11 </span></p>
<p style="top:389.1pt;left:483.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">doses over 3&#xa0;days</span></p>
<p style="top:298.9pt;left:454.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">14&#xa0;days</span></p>
<p style="top:250.7pt;left:454.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Adverse events and </span></p>
<p style="top:250.7pt;left:464.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">antioxidant reserve</span></p>
<p style="top:160.2pt;left:454.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 No adverse events in the NAC </span></p>
<p style="top:153.2pt;left:464.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">group</span></p>
<p style="top:707.7pt;left:508.7pt;line-height:6.5pt"><i><span style="font-family:Arial,serif;font-size:6.5pt">COWA, controlled oral word association test; GCS, Glasgow coma scale; NAC, N-acetyl cysteine; NR, not reported; SPECT, single-photon emission computed tomography.</span></i></p>
<p style="top:741.9pt;left:294.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">3</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>
<p style="top:61.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">MeSH headings and the keywords &#x201c;acetyl-cysteine&#x201d; or &#x201c;acetyl-</span></p>
<p style="top:72.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cysteine&#x201d; or &#x201c;cysteine hydrochloride&#x201d; or &#x201c;cystine l-cysteine&#x201d; or </span></p>
<p style="top:84.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x201c;NAC&#x201d; or &#x201c;</span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">N-</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">acetyl-B-cysteine&#x201d; or &#x201c;</span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">N-</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">acetyl-l-cysteine&#x201d; or </span></p>
<p style="top:95.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x201c;</span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">N-</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">acetylcysteine&#x201d; AND &#x201c;brain injury&#x201d; or &#x201c;trauma.&#x201d;</span></p>
<p style="top:116.9pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">eligibility criteria and Study Selection</span></b></p>
<p style="top:130.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">We included experimental studies in humans or animals that </span></p>
<p style="top:141.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">measured the neurofunctional outcome (primary outcome) post </span></p>
<p style="top:153.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">NAC or NACA use in patients with TBI or in animal models </span></p>
<p style="top:164.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of brain injury. To be included, studies should have performed </span></p>
<p style="top:176.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">standardized neurocognitive or behavioral tests to measure </span></p>
<p style="top:187.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">neurofunctional outcome. We also included studies that meas-</span></p>
<p style="top:199.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ured levels of biomarkers of oxidative stress, inflammation or </span></p>
<p style="top:210.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cell death (secondary outcomes). Studies were required to have </span></p>
<p style="top:222.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">at least one comparator group without NAC administration or </span></p>
<p style="top:233.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">placebo, including before and after intervention comparison. We </span></p>
<p style="top:245.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">included human studies involving adult or pediatric patients. </span></p>
<p style="top:256.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">We excluded studies involving isolated spinal cord injuries, case </span></p>
<p style="top:268.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">reports, case series, and conference proceedings. Two of the </span></p>
<p style="top:280.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">review authors (JB and UA) not blinded to journal, institution </span></p>
<p style="top:291.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">or authors, independently screened the abstracts of identified </span></p>
<p style="top:303.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">studies, and determined the eligibility of each study. Each </span></p>
<p style="top:314.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">author screened the titles and abstracts of every record retrieved </span></p>
<p style="top:326.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">to determine which of the studies would be assessed further. </span></p>
<p style="top:337.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">If it was clear from the title and abstract that the article was </span></p>
<p style="top:349.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">irrelevant, the article was rejected. Full texts of the studies with </span></p>
<p style="top:360.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">questionable eligibility or considered eligible, were retrieved </span></p>
<p style="top:372.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in this phase for evaluation. The reference lists of the retrieved </span></p>
<p style="top:383.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">articles were also searched for additional citations. In case of </span></p>
<p style="top:395.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">disagreement, consensus was reached by discussion with the </span></p>
<p style="top:406.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">senior author (LTDL).</span></p>
<p style="top:427.4pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">interventions</span></b></p>
<p style="top:440.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">In both human and animal studies, we included all regimens of </span></p>
<p style="top:452.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">NAC and NACA used (different loading and maintenance doses, </span></p>
<p style="top:463.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">intervals, duration and routes). Information about which placebo </span></p>
<p style="top:475.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and its regimen was also retrieved. A summary of the characteris-</span></p>
<p style="top:486.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tics of included studies is available in </span><b><span style="font-family:MinionPro,serif;font-size:9.5pt">Tables&#xa0;1</span></b><span style="font-family:MinionPro,serif;font-size:9.5pt"> and </span><b><span style="font-family:MinionPro,serif;font-size:9.5pt">2</span></b><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:507.9pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Outcome measures</span></b></p>
<p style="top:521.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The primary outcome in this review was the neurofunctional </span></p>
<p style="top:532.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">status of the participants after administration of NAC or NACA, </span></p>
<p style="top:544.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">compared with a control group, during the follow-up period </span></p>
<p style="top:555.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">established in each study. Several tests for assessment of different </span></p>
<p style="top:567.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">levels of neurocognition have been previously validated in the </span></p>
<p style="top:578.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">human and animal literature. For example, the use of novel object </span></p>
<p style="top:590.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">recognition in Morris Water Maze Task (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">57</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) for assessment of </span></p>
<p style="top:601.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">neurocognition, and Y-maze (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), for assessment of psychomo-</span></p>
<p style="top:613.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tor skills, both used in animals. Other tests were used in humans, </span></p>
<p style="top:624.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">such as the MicroCog</span><sup><span style="font-family:STIXGeneral,serif;font-size:5.5pt">&#xae;</span></sup><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2014;Assessment of Cognitive Functioning </span></p>
<p style="top:636.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(MACF) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">58</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), Controlled Oral Word Association test with ani-</span></p>
<p style="top:647.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mal naming (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">59</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), Romberg test (balance) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">60</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), and the dynamic </span></p>
<p style="top:659.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">gait index (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">61</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). In addition, assessment of post-traumatic </span></p>
<p style="top:670.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">symptoms such as hearing loss, headache, dizziness, memory </span></p>
<p style="top:682.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">loss, and sleep disturbances were also conducted (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">35</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). The sec-</span></p>
<p style="top:693.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ondary outcomes were tissue biomarkers of inflammation, such </span></p>
<p style="top:705.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">as pro-inflammatory cytokines [e.g., interleukin (IL)-1</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&#x3b2;</span><span style="font-family:MinionPro,serif;font-size:9.5pt"> (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">62</span><span style="font-family:MinionPro,serif;font-size:9.5pt">),  </span></p>


<p style="top:61.5pt;left:45.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">taBle 2</span></b><span style="font-family:Arial,serif;font-size:7.0pt"> | Characteristics of 20 animal studies (21 experiments).</span></p>
<p style="top:78.1pt;left:45.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Reference</span></b></p>
<p style="top:78.1pt;left:98.6pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">animal model</span></b></p>
<p style="top:78.1pt;left:179.7pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">N</span></i></b></p>
<p style="top:78.1pt;left:196.6pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">injury type</span></b></p>
<p style="top:78.1pt;left:254.2pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">control group(s)</span></b></p>
<p style="top:78.1pt;left:324.5pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">intervention</span></b></p>
<p style="top:78.1pt;left:390.7pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">Via</span></i></b></p>
<p style="top:78.1pt;left:410.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">initiation of </span></b></p>
<p style="top:87.6pt;left:410.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">intervention</span></b></p>
<p style="top:78.1pt;left:460.1pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Other doses</span></b></p>
<p style="top:78.1pt;left:516.5pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Follow-up</span></b></p>
<p style="top:104.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Abdel-Baki </span></p>
<p style="top:114.1pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">37</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:104.6pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:114.1pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">250&#x2013;300&#xa0;g</span></p>
<p style="top:104.6pt;left:179.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NR</span></p>
<p style="top:104.6pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">CCI, moderate</span></p>
<p style="top:104.9pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. Sham injury&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;NS</span></p>
<p style="top:114.4pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. Injury and NS</span></p>
<p style="top:104.6pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 150&#xa0;mg/kg</span></p>
<p style="top:104.6pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:104.6pt;left:410.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1&#xa0;h</span></p>
<p style="top:104.6pt;left:460.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Once daily on </span></p>
<p style="top:114.1pt;left:460.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">days 1 and 2</span></p>
<p style="top:104.6pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1&#xa0;week</span></p>
<p style="top:128.0pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Chen et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">38</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:128.0pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Wistar rats, 250&#x2013;300&#xa0;g</span></p>
<p style="top:128.0pt;left:179.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">51</span></p>
<p style="top:128.0pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Weight drop, </span></p>
<p style="top:137.5pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">moderate</span></p>
<p style="top:128.0pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. Sham injury&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;NS</span></p>
<p style="top:137.5pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. Injury and saline</span></p>
<p style="top:128.0pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 150&#xa0;mg/kg</span></p>
<p style="top:128.0pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:128.0pt;left:410.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">15&#xa0;min</span></p>
<p style="top:128.0pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Once daily on </span></p>
<p style="top:137.5pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">days 1, 2, and 3</span></p>
<p style="top:128.0pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">3&#xa0;days</span></p>
<p style="top:151.1pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Du et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">39</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:151.1pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Long Evans pigmented </span></p>
<p style="top:160.6pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">rats, 360&#x2013;400&#xa0;g</span></p>
<p style="top:151.1pt;left:179.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">74</span></p>
<p style="top:151.1pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Blast exposure, </span></p>
<p style="top:160.6pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">14psi, mild</span></p>
<p style="top:151.1pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Normal control</span></p>
<p style="top:151.1pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 300&#xa0;mg/kg</span></p>
<p style="top:151.1pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:151.1pt;left:410.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1&#xa0;h</span></p>
<p style="top:151.1pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Twice daily on </span></p>
<p style="top:160.6pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">days 1 and 2</span></p>
<p style="top:151.1pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">7, 14, and </span></p>
<p style="top:160.6pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">21&#xa0;days</span></p>
<p style="top:160.6pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">HPN-07 98.5%</span></p>
<p style="top:174.2pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Eakin et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">40</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:174.2pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1. Sprague&#x2013;Dawley rats. </span></p>
<p style="top:183.7pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">350&#x2013;400&#xa0;g</span></p>
<p style="top:174.2pt;left:179.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">26</span></p>
<p style="top:174.2pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">FPI, 1.8&#x2013;1.9&#xa0;atm, </span></p>
<p style="top:183.7pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">mild</span></p>
<p style="top:174.2pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. Sham</span></p>
<p style="top:183.7pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. Injury</span></p>
<p style="top:174.2pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 50&#xa0;mg/kg</span></p>
<p style="top:174.2pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:174.2pt;left:410.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">30&#xa0;min</span></p>
<p style="top:174.2pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Once daily on </span></p>
<p style="top:183.7pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">days 1, 2 and 3</span></p>
<p style="top:174.2pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">14&#xa0;days</span></p>
<p style="top:197.4pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Eakin et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">40</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:197.4pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">ICR mice, 30&#x2013;40&#xa0;g</span></p>
<p style="top:197.4pt;left:179.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">32</span></p>
<p style="top:197.4pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Weight drop, </span></p>
<p style="top:206.9pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">~30&#xa0;g, mild</span></p>
<p style="top:197.4pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. Sham vehicle </span></p>
<p style="top:206.9pt;left:264.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(DMSO)</span></p>
<p style="top:216.4pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. Sham&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;drug</span></p>
<p style="top:225.9pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 3. Injury</span></p>
<p style="top:197.4pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 100&#xa0;mg/kg</span></p>
<p style="top:197.4pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:197.4pt;left:410.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1&#xa0;h</span></p>
<p style="top:197.4pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NR</span></p>
<p style="top:197.4pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">7&#xa0;days</span></p>
<p style="top:210.9pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Topiramate  </span></p>
<p style="top:220.4pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">30&#xa0;mg/kg</span></p>
<p style="top:210.9pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">30&#xa0;days</span></p>
<p style="top:239.5pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Ellis et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">41</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:239.5pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Cats</span></p>
<p style="top:239.5pt;left:179.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">17</span></p>
<p style="top:239.5pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">FPI, mild</span></p>
<p style="top:239.5pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Injury</span></p>
<p style="top:239.5pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1. Pre-TBI  </span></p>
<p style="top:249.0pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">326&#xa0;mg/kg</span></p>
<p style="top:239.5pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:239.5pt;left:410.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">30&#xa0;min</span></p>
<p style="top:239.5pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NR</span></p>
<p style="top:239.5pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">80&#xa0;min</span></p>
<p style="top:258.5pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2. Post-TBI </span></p>
<p style="top:268.0pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">163&#xa0;mg/kg</span></p>
<p style="top:281.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Ewert et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">42</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:281.6pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Long Evans pigmented </span></p>
<p style="top:291.1pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">rats, 360&#x2013;400&#xa0;g</span></p>
<p style="top:281.6pt;left:179.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">48</span></p>
<p style="top:281.6pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Blast exposure,</span></p>
<p style="top:291.1pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">~ 14psi, mild</span></p>
<p style="top:281.6pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Injury </span></p>
<p style="top:281.6pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 300&#xa0;mg/kg</span></p>
<p style="top:281.6pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:281.6pt;left:410.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1&#xa0;h</span></p>
<p style="top:281.6pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Twice daily for </span></p>
<p style="top:291.1pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2&#xa0;days</span></p>
<p style="top:281.6pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">3 and 24&#xa0;h</span></p>
<p style="top:291.1pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">HPN-07 300&#xa0;g/kg</span></p>
<p style="top:291.1pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">7&#xa0;days and </span></p>
<p style="top:300.6pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">21days</span></p>
<p style="top:314.2pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Gunther et&#xa0;al. </span></p>
<p style="top:323.7pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">43</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:314.2pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:323.7pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">250&#x2013;400&#xa0;g</span></p>
<p style="top:314.2pt;left:179.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">24</span></p>
<p style="top:314.2pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Penetrating </span></p>
<p style="top:323.7pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">ballistic like, </span></p>
<p style="top:333.2pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">moderate</span></p>
<p style="top:314.2pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. Injury</span></p>
<p style="top:323.7pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. Sham surgery</span></p>
<p style="top:314.2pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NACA 300&#xa0;mg/kg</span></p>
<p style="top:314.2pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:314.2pt;left:410.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2&#xa0;min</span></p>
<p style="top:314.2pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">24&#xa0;h survivors </span></p>
<p style="top:323.7pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">300&#xa0;mg/kg</span></p>
<p style="top:314.2pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2 and 24&#xa0;h</span></p>
<p style="top:346.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Haber et&#xa0;al. </span></p>
<p style="top:356.4pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">44</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:346.9pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:356.4pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">250&#x2013;300&#xa0;g</span></p>
<p style="top:346.9pt;left:179.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NR CCI, moderate</span></p>
<p style="top:346.9pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. Sham&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;NS</span></p>
<p style="top:356.4pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. Injury&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;NS</span></p>
<p style="top:365.9pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 3. Minocycline </span></p>
<p style="top:375.4pt;left:264.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">45&#xa0;mg/kg</span></p>
<p style="top:346.9pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1. NAC 150&#xa0;mg/kg</span></p>
<p style="top:346.9pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:346.9pt;left:410.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1&#xa0;h</span></p>
<p style="top:346.9pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Once daily on </span></p>
<p style="top:356.4pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">days 1 and 2</span></p>
<p style="top:346.9pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">31&#xa0;days</span></p>
<p style="top:356.4pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2.  NAC 150&#xa0;mg/</span></p>
<p style="top:365.9pt;left:332.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">kg&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;minocycline </span></p>
<p style="top:375.4pt;left:332.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">45&#xa0;mg/kg</span></p>
<p style="top:389.0pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Hicdonmez </span></p>
<p style="top:398.5pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">45</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:389.0pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:398.5pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">280&#x2013;320&#xa0;g</span></p>
<p style="top:389.0pt;left:179.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">36</span></p>
<p style="top:389.0pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Weight drop </span></p>
<p style="top:398.5pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">~0.5J, moderate</span></p>
<p style="top:389.0pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> (1) No injury</span></p>
<p style="top:398.5pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> (2) Injury</span></p>
<p style="top:389.0pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 150&#xa0;mg/kg</span></p>
<p style="top:389.0pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:389.0pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">15&#xa0;min</span></p>
<p style="top:389.0pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NR</span></p>
<p style="top:389.0pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2 and 12&#xa0;h</span></p>
<p style="top:412.1pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Kawoos et&#xa0;al. </span></p>
<p style="top:421.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">46</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:412.1pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:421.6pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">300&#x2013;350&#xa0;g</span></p>
<p style="top:412.1pt;left:179.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">88</span></p>
<p style="top:412.1pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Blast </span></p>
<p style="top:421.6pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">overpressure, </span></p>
<p style="top:431.1pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">mild</span></p>
<p style="top:412.1pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Placebo (6 groups </span></p>
<p style="top:421.6pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">based on repetitive </span></p>
<p style="top:431.1pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">BOP)</span></p>
<p style="top:412.1pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NACA 500&#xa0;mg/kg </span></p>
<p style="top:421.6pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">in each group, for 6 </span></p>
<p style="top:431.1pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">different groups</span></p>
<p style="top:412.1pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:412.1pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2&#xa0;h in 6 </span></p>
<p style="top:421.6pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">groups and </span></p>
<p style="top:431.1pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">15&#xa0;min prior </span></p>
<p style="top:440.6pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">TBI in 1 group</span></p>
<p style="top:412.1pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1 group: NACA </span></p>
<p style="top:421.6pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">at 2&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;4&#xa0;h post </span></p>
<p style="top:431.1pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">TBI</span></p>
<p style="top:412.1pt;left:516.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">7&#xa0;days</span></p>
<p style="top:454.2pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Naziroglu et&#xa0;al. </span></p>
<p style="top:463.7pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">47</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:454.2pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:463.7pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">330&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">&#xb1;</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;20g</span></p>
<p style="top:454.2pt;left:179.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">36</span></p>
<p style="top:454.2pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Weight drop </span></p>
<p style="top:463.7pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">contusion, </span></p>
<p style="top:473.2pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">moderate</span></p>
<p style="top:454.2pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. No injury</span></p>
<p style="top:463.7pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. TBI</span></p>
<p style="top:473.2pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 3. TBI&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;Se</span></p>
<p style="top:454.2pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 150&#xa0;mg/kg</span></p>
<p style="top:454.2pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Oral</span></p>
<p style="top:454.2pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1&#xa0;h</span></p>
<p style="top:454.2pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Once at 24&#xa0;h, </span></p>
<p style="top:463.7pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">48&#xa0;h, and 72&#xa0;h</span></p>
<p style="top:454.2pt;left:516.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">3&#xa0;days</span></p>
<p style="top:486.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Pandya et&#xa0;al. </span></p>
<p style="top:496.4pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">48</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:486.9pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:496.4pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">300&#x2013;350&#xa0;g</span></p>
<p style="top:486.9pt;left:179.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">51</span></p>
<p style="top:486.9pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">CCI, moderate</span></p>
<p style="top:486.9pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">TBI&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;vehicle</span></p>
<p style="top:486.9pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1. NAC 150&#xa0;mg</span></p>
<p style="top:486.9pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:486.9pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">5&#x2013;30&#xa0;min</span></p>
<p style="top:486.9pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">18.5&#xa0;mg/kg/h </span></p>
<p style="top:496.4pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC, NACA or </span></p>
<p style="top:505.9pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">vehicle</span></p>
<p style="top:486.9pt;left:516.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">25&#xa0;h to </span></p>
<p style="top:496.4pt;left:516.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">15&#xa0;days</span></p>
<p style="top:496.4pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2.  NACA 150&#xa0;mg/</span></p>
<p style="top:505.9pt;left:332.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">kg and 18.5&#xa0;mg/</span></p>
<p style="top:515.4pt;left:332.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">kg/h</span></p>
<p style="top:529.0pt;left:45.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Senol et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">20</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:529.0pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:538.5pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">300&#x2013;340&#xa0;g</span></p>
<p style="top:529.0pt;left:179.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">36</span></p>
<p style="top:529.0pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Weight drop,</span></p>
<p style="top:538.5pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">moderate</span></p>
<p style="top:529.0pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. No injury</span></p>
<p style="top:538.5pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. TBI</span></p>
<p style="top:548.0pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 3. TBI&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;Se</span></p>
<p style="top:529.0pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 150&#xa0;mg/kg</span></p>
<p style="top:529.0pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Oral</span></p>
<p style="top:529.0pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1&#xa0;h</span></p>
<p style="top:529.0pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Once at 24&#xa0;h, </span></p>
<p style="top:538.5pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">48&#xa0;h, and 72&#xa0;h</span></p>
<p style="top:529.0pt;left:516.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">4&#xa0;weeks</span></p>
<p style="top:561.6pt;left:45.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Silva et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">49</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:561.6pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Wistar rats,</span></p>
<p style="top:571.1pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">270&#x2013;300&#xa0;g</span></p>
<p style="top:561.6pt;left:179.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NR</span></p>
<p style="top:561.6pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">FPI, moderate</span></p>
<p style="top:561.6pt;left:254.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Injury&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;NS </span></p>
<p style="top:561.6pt;left:324.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 100&#xa0;mg/kg</span></p>
<p style="top:561.6pt;left:390.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Oral</span></p>
<p style="top:561.6pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Immediately</span></p>
<p style="top:561.6pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Once daily for </span></p>
<p style="top:571.1pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">5&#xa0;weeks</span></p>
<p style="top:561.6pt;left:516.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">5&#xa0;weeks</span></p>
<p style="top:584.7pt;left:45.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Thomale et&#xa0;al. </span></p>
<p style="top:594.2pt;left:45.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">50</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:584.7pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:594.2pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">300&#x2013;350&#xa0;g</span></p>
<p style="top:584.7pt;left:179.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">48</span></p>
<p style="top:584.7pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">CCI, moderate</span></p>
<p style="top:584.7pt;left:254.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1.  Injury&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;NS</span></p>
<p style="top:584.7pt;left:324.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 163&#xa0;mg/kg</span></p>
<p style="top:584.7pt;left:390.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:584.7pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Immediately</span></p>
<p style="top:584.7pt;left:460.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2 and 4&#xa0;h</span></p>
<p style="top:584.7pt;left:516.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">24&#xa0;h</span></p>
<p style="top:607.9pt;left:45.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Thomale et&#xa0;al. </span></p>
<p style="top:617.4pt;left:45.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">51</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:607.9pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:617.4pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">300&#x2013;350&#xa0;g</span></p>
<p style="top:607.9pt;left:179.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">62</span></p>
<p style="top:607.9pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">CCI, moderate</span></p>
<p style="top:607.9pt;left:254.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1.  Injury&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;NS</span></p>
<p style="top:607.9pt;left:324.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 163&#xa0;mg/kg</span></p>
<p style="top:607.9pt;left:390.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:607.9pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">15&#xa0;min</span></p>
<p style="top:607.9pt;left:460.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2 and 4&#xa0;h</span></p>
<p style="top:607.9pt;left:516.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">24&#xa0;h</span></p>
<p style="top:631.0pt;left:45.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Xiong et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">52</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:631.0pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:640.5pt;left:98.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">200&#x2013;350&#xa0;g</span></p>
<p style="top:631.0pt;left:179.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NR</span></p>
<p style="top:631.0pt;left:196.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">CCI, moderate</span></p>
<p style="top:631.0pt;left:254.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. Sham</span></p>
<p style="top:640.5pt;left:254.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. Injury</span></p>
<p style="top:650.0pt;left:254.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 3. Vehicle</span></p>
<p style="top:631.0pt;left:324.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 163&#xa0;mg/kg</span></p>
<p style="top:631.0pt;left:390.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:631.0pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">4 groups:</span></p>
<p style="top:645.2pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. 5&#xa0;min </span></p>
<p style="top:654.7pt;left:420.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">before</span></p>
<p style="top:664.2pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. 30&#xa0;min </span></p>
<p style="top:673.7pt;left:420.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">after</span></p>
<p style="top:683.2pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 3. 1&#xa0;h after</span></p>
<p style="top:692.7pt;left:410.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 4. 2&#xa0;h after</span></p>
<p style="top:631.0pt;left:460.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2 groups post </span></p>
<p style="top:640.5pt;left:460.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">TBI:</span></p>
<p style="top:654.7pt;left:460.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1. 5&#xa0;m and </span></p>
<p style="top:664.2pt;left:470.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">15&#xa0;m</span></p>
<p style="top:673.7pt;left:460.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1. 5&#xa0;m and </span></p>
<p style="top:683.2pt;left:470.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">30&#xa0;m</span></p>
<p style="top:631.0pt;left:516.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">12&#xa0;hours</span></p>
<p style="top:640.5pt;left:516.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">14&#xa0;days</span></p>
<p style="top:741.9pt;left:294.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">4</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>
<p style="top:707.9pt;left:514.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(</span><i><span style="font-family:Arial,serif;font-size:7.0pt">Continued</span></i><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>


<p style="top:78.1pt;left:45.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Reference</span></b></p>
<p style="top:78.1pt;left:98.6pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">animal model</span></b></p>
<p style="top:78.1pt;left:179.7pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">N</span></i></b></p>
<p style="top:78.1pt;left:196.6pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">injury type</span></b></p>
<p style="top:78.1pt;left:254.2pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">control group(s)</span></b></p>
<p style="top:78.1pt;left:324.5pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">intervention</span></b></p>
<p style="top:78.1pt;left:390.7pt;line-height:7.0pt"><b><i><span style="font-family:Arial,serif;font-size:7.0pt">Via</span></i></b></p>
<p style="top:78.1pt;left:410.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">initiation of </span></b></p>
<p style="top:87.6pt;left:410.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">intervention</span></b></p>
<p style="top:78.1pt;left:460.1pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Other doses</span></b></p>
<p style="top:78.1pt;left:516.5pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Follow-up</span></b></p>
<p style="top:103.2pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Xiong et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">53</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:103.2pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:112.7pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">200&#x2013;350&#xa0;g</span></p>
<p style="top:103.2pt;left:179.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NR</span></p>
<p style="top:103.2pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">CCI, moderate</span></p>
<p style="top:103.2pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. Sham</span></p>
<p style="top:112.7pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. Injury</span></p>
<p style="top:103.2pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 163&#xa0;mg/kg</span></p>
<p style="top:103.2pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:103.2pt;left:410.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">30&#xa0;min</span></p>
<p style="top:103.2pt;left:460.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NR</span></p>
<p style="top:103.2pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1, 4 and </span></p>
<p style="top:112.7pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">12&#xa0;h</span></p>
<p style="top:122.2pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1 and </span></p>
<p style="top:131.7pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">14&#xa0;days</span></p>
<p style="top:145.4pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yiand Hazell </span></p>
<p style="top:154.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">(</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">54</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:145.4pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:154.9pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">200&#x2013;350&#xa0;g</span></p>
<p style="top:145.4pt;left:179.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">64</span></p>
<p style="top:145.4pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">FPI, moderate</span></p>
<p style="top:145.4pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. Sham&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;NS</span></p>
<p style="top:154.9pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. Injury&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;NS</span></p>
<p style="top:145.4pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 163&#xa0;mg/kg</span></p>
<p style="top:145.4pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:145.4pt;left:410.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">5&#xa0;min</span></p>
<p style="top:145.4pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">6 and 24&#xa0;h</span></p>
<p style="top:145.4pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">6 and 24&#xa0;h</span></p>
<p style="top:164.4pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yi et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">55</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:164.4pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Sprague&#x2013;Dawley rats, </span></p>
<p style="top:173.9pt;left:98.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">200&#x2013;350&#xa0;g</span></p>
<p style="top:164.4pt;left:179.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">66</span></p>
<p style="top:164.4pt;left:196.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">FPI, moderate</span></p>
<p style="top:164.4pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1. Sham&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;NS</span></p>
<p style="top:173.9pt;left:254.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2. Injury&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;NS</span></p>
<p style="top:164.4pt;left:324.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NAC 163&#xa0;mg/kg</span></p>
<p style="top:164.4pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">IP </span></p>
<p style="top:164.4pt;left:410.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">5&#xa0;min</span></p>
<p style="top:164.4pt;left:460.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NR</span></p>
<p style="top:164.4pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">6 and 24&#xa0;h</span></p>
<p style="top:173.9pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">3 and </span></p>
<p style="top:183.4pt;left:516.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">7&#xa0;days</span></p>
<p style="top:199.1pt;left:45.4pt;line-height:6.5pt"><i><span style="font-family:Arial,serif;font-size:6.5pt">atm, atmospheric pressure; BOP, blast overpressure; CCI, controlled cortical impact; DMSO, dimethyl sulfoxide; FPI, fluid percussion injury; HPN, 2,4-disulfonyl </span></i><span style="font-family:STIXGeneral,serif;font-size:6.5pt">&#x3b1;</span><i><span style="font-family:Arial,serif;font-size:6.5pt">-phenyl tertiary </span></i></p>
<p style="top:208.1pt;left:45.4pt;line-height:6.5pt"><i><span style="font-family:Arial,serif;font-size:6.5pt">butyl nitrone; ICR, imprinting control region; IP, intra-peritoneal; NACA, n-acetylcysteine amide; NAC, n-acetylcysteine; NR, not reported; NS, normal saline; PSI, pounds per square </span></i></p>
<p style="top:217.1pt;left:45.4pt;line-height:6.5pt"><i><span style="font-family:Arial,serif;font-size:6.5pt">inch; Se, selenium; TBI, traumatic brain injury.</span></i></p>
<p style="top:741.9pt;left:294.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">5</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>
<p style="top:253.3pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tumor necrosis factor alpha (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">63</span><span style="font-family:MinionPro,serif;font-size:9.5pt">)], neural injury [e.g., glial </span></p>
<p style="top:264.8pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">fibrillary acidic protein (GFAP) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">64</span><span style="font-family:MinionPro,serif;font-size:9.5pt">)], neurodegeneration [e.g., </span></p>
<p style="top:276.3pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">amyloid-</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&#x3b2;</span><span style="font-family:MinionPro,serif;font-size:9.5pt"> (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">64</span><span style="font-family:MinionPro,serif;font-size:9.5pt">)], apoptosis (e.g., deoxy-nucleotide transferase </span></p>
<p style="top:287.8pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">dUTP nick and labeling) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">38</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), and oxidative stress [e.g., cytosolic </span></p>
<p style="top:299.3pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">free Ca</span><sup><span style="font-family:STIXGeneral,serif;font-size:5.5pt">++</span></sup><span style="font-family:MinionPro,serif;font-size:9.5pt">, cytosolic ROS (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">65</span><span style="font-family:MinionPro,serif;font-size:9.5pt">)].</span></p>
<p style="top:320.3pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Risk of Bias assessment</span></b></p>
<p style="top:333.8pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Risk of bias was assessed in duplicate for each study included. Any </span></p>
<p style="top:345.3pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">disagreement was resolved through discussion and consensus. </span></p>
<p style="top:356.8pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Each included study was classified as a randomized controlled </span></p>
<p style="top:368.3pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">trial (RCT) or a non-randomized study. We assessed risk of bias </span></p>
<p style="top:379.8pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in each human study incorporated describing the risks (low-risk, </span></p>
<p style="top:391.3pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">high-risk, and unclear risk) for selection bias, performance bias, </span></p>
<p style="top:402.8pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">detection bias, attrition bias, reporting bias, and other bias. For </span></p>
<p style="top:414.3pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">animal studies, we used the tool proposed by Krauth et&#xa0;al. (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">66</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) </span></p>
<p style="top:425.8pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">which includes randomization, allocation concealment, blinding, </span></p>
<p style="top:437.3pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sample size, ethical compliance, statistical methods, outcome </span></p>
<p style="top:448.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">assessment, and follow-up.</span></p>
<p style="top:469.8pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">analysis</span></b></p>
<p style="top:483.3pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Clinical and methodological heterogeneity across the studies were </span></p>
<p style="top:494.8pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">assessed by examining study design, details on subjects, baseline </span></p>
<p style="top:506.3pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">data, interventions and outcomes, to determine whether the </span></p>
<p style="top:517.8pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">studies were sufficiently similar or not. Large heterogeneity, and </span></p>
<p style="top:529.3pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">the absence of common outcome measures reported, precluded </span></p>
<p style="top:540.8pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">meta-analyses. Therefore, all studies were analyzed qualitatively </span></p>
<p style="top:552.3pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">with a descriptive systematic approach.</span></p>
<p style="top:579.4pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">ReSUltS</span></b></p>
<p style="top:601.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The database search identified 251 potential studies for inclu-</span></p>
<p style="top:612.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sion. After completion of the screening process, 23 studies were </span></p>
<p style="top:624.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">included in the qualitative analysis (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">34</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">55</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Three studies </span></p>
<p style="top:635.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">were conducted in humans (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">34</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">36</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) and 20 in animals (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">37</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">45</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span></p>
<p style="top:647.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">47</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">55</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Other studies were excluded because they did not meet </span></p>
<p style="top:659.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">inclusion criteria, i.e., commentaries, conference abstracts, case </span></p>
<p style="top:670.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">reports and case series, or studies including spinal cord injuries. </span></p>
<p style="top:682.0pt;left:45.4pt;line-height:9.5pt"><b><span style="font-family:MinionPro,serif;font-size:9.5pt">Figure&#xa0;1</span></b><span style="font-family:MinionPro,serif;font-size:9.5pt"> demonstrates the flow of the screening process. Studies </span></p>
<p style="top:693.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">excluded during the review process are reported in Supplementary </span></p>
<p style="top:705.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">SI in Supplementary Material.</span></p>
<p style="top:253.0pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">clinical and methodological </span></b></p>
<p style="top:267.0pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">characteristics</span></b></p>
<p style="top:280.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The three studies conducted in humans were represented by two </span></p>
<p style="top:292.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">RCT (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">35</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">36</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) and one observational cohort study (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">34</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) (</span><b><span style="font-family:MinionPro,serif;font-size:9.5pt">Tables&#xa0;1</span></b><span style="font-family:MinionPro,serif;font-size:9.5pt"> </span></p>
<p style="top:303.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and </span><b><span style="font-family:MinionPro,serif;font-size:9.5pt">2</span></b><span style="font-family:MinionPro,serif;font-size:9.5pt">). The study with the largest sample size enrolled 81 active </span></p>
<p style="top:315.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">duty military personnel or veterans with blast-related mild TBI </span></p>
<p style="top:326.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">35</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), whereas the other RCT recruited 14 pediatric patients with </span></p>
<p style="top:338.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">severe TBI (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">36</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). The observational study (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">34</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) was conducted in </span></p>
<p style="top:349.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">30 retired professional football players who sustained repeated </span></p>
<p style="top:361.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">head impacts over extended periods of time with evidence of </span></p>
<p style="top:372.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">brain damage (mTBI/concussion) and cognitive impairment.</span></p>
<p style="top:384.0pt;left:317.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The 20 animal studies (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">37</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">55</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) included 21 experiments </span></p>
<p style="top:395.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">with over 700 animals in total. Nineteen studies included rats </span></p>
<p style="top:407.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">n</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;700), however, five studies did not report sample size (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">37</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span></p>
<p style="top:418.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">44</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">49</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">52</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">53</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). One study examined mice (</span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">n</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;32) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), and one </span></p>
<p style="top:430.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">included cats (</span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">n</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;17) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">41</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Sprague&#x2013;Dawley rats were included </span></p>
<p style="top:441.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in 15 studies (</span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">n</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;491) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">37</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">43</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">48</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">50</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">55</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Studies used </span></p>
<p style="top:453.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">different brain injury models, such as controlled cortical impact </span></p>
<p style="top:464.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in seven experiments (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">37</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">44</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">48</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">50</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">53</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), weight drop in five </span></p>
<p style="top:476.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">experiments (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">38</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">45</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">47</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), fluid percussion injury in five </span></p>
<p style="top:487.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">experiments (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">41</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">49</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">54</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">55</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), blast exposure in three experi-</span></p>
<p style="top:499.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ments (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">39</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">42</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">46</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), and ballistic-like TBI in one experiment (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">43</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). </span></p>
<p style="top:510.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">A moderate injury was inflicted on animals in 15 of these experi-</span></p>
<p style="top:522.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ments (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">37</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">38</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">43</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">45</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">47</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">55</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) and mild injury in 6 experiments </span></p>
<p style="top:533.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">39</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">42</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">46</span><span style="font-family:MinionPro,serif;font-size:9.5pt">).</span></p>
<p style="top:554.5pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">interventions</span></b></p>
<p style="top:568.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Human studies used different regimens of NAC. For example, </span></p>
<p style="top:579.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in the placebo-controlled RCT conducted involving military </span></p>
<p style="top:591.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">members (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">35</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), a loading dose of 4&#xa0; g was administered orally </span></p>
<p style="top:602.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">within 72&#xa0;h of mild TBI followed by 4&#xa0;g/day for 4&#xa0;days, and 3&#xa0;g/</span></p>
<p style="top:614.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">day for 3&#xa0;days. In the pediatric placebo-controlled trial (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">36</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), NAC </span></p>
<p style="top:625.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">was administered with probenecid with loading dosages of 140 </span></p>
<p style="top:637.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and 25&#xa0;mg/kg, respectively. A total of 17 maintenance doses of </span></p>
<p style="top:648.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">70&#xa0;mg/kg of NAC were administered over three days along with </span></p>
<p style="top:660.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">11 maintenance doses of 10&#xa0;mg/kg of probenecid. In the non-</span></p>
<p style="top:671.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">randomized trial (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">34</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), NAC was administered as one of the active </span></p>
<p style="top:683.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">agents of dietary supplements with no clarification of regimen.</span></p>
<p style="top:694.5pt;left:317.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">In the animal studies, the loading doses of NAC ranged from </span></p>
<p style="top:706.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">100&#x2013;326&#xa0;mg/kg with median dose of 163&#xa0;mg/kg used in seven </span></p>
<p style="top:61.5pt;left:45.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">taBle 2 </span></b><span style="font-family:Arial,serif;font-size:7.0pt">| Continued</span></p>


<img style="position:absolute;transform:matrix(0,-.3451111,.34804959,0,59.534715,227.89826)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAASAAAABRCAIAAAD96OwHAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAA/0lEQVR4nO3TUQkAIBTAwNc/m1HsoCmGIAcXYD+btQ8QmecF8DGD
QchgEDIYhAwGIYNByGAQMhiEDAYhg0HIYBAyGIQMBiGDQchgEDIYhAwGIYNByGAQ
MhiEDAYhg0HIYBAyGIQMBiGDQchgEDIYhAwGIYNByGAQMhiEDAYhg0HIYBAyGIQM
BiGDQchgEDIYhAwGIYNByGAQMhiEDAYhg0HIYBAyGIQMBiGDQchgEDIYhAwGIYNB
yGAQMhiEDAYhg0HIYBAyGIQMBiGDQchgEDIYhAwGIYNByGAQMhiEDAYhg0HIYBAy
GIQMBiGDQchgEDIYhAwGIYNByGAQMhiELvqcclohBiIOAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(0,-.34447069,.34875996,0,59.214754,469.45826)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAASEAAABPCAIAAAAr9uTSAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAA+klEQVR4nO3TUQkAIBTAwNc/m1HsoCmGIAcXYD+btQ/QmecF8DeP
Qctj0PIYtDwGLY9By2PQ8hi0PAYtj0HLY9DyGLQ8Bi2PQctj0PIYtDwGLY9By2PQ
8hi0PAYtj0HLY9DyGLQ8Bi2PQctj0PIYtDwGLY9By2PQ8hi0PAYtj0HLY9DyGLQ8
Bi2PQctj0PIYtDwGLY9By2PQ8hi0PAYtj0HLY9DyGLQ8Bi2PQctj0PIYtDwGLY9B
y2PQ8hi0PAYtj0HLY9DyGLQ8Bi2PQctj0PIYtDwGLY9By2PQ8hi0PAYtj0HLY9Dy
GLQ8Bi2PQctj0PIYtDwGLY9B6wKp9CzIM8X0uAAAAABJRU5ErkJggg==">
<img style="position:absolute;transform:matrix(0,-.34455569,.34804974,0,59.37474,347.8182)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAASAAAABRCAIAAAD96OwHAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAA/0lEQVR4nO3TUQkAIBTAwNc/m1HsoCmGIAcXYD+btQ8QmecF8DGD
QchgEDIYhAwGIYNByGAQMhiEDAYhg0HIYBAyGIQMBiGDQchgEDIYhAwGIYNByGAQ
MhiEDAYhg0HIYBAyGIQMBiGDQchgEDIYhAwGIYNByGAQMhiEDAYhg0HIYBAyGIQM
BiGDQchgEDIYhAwGIYNByGAQMhiEDAYhg0HIYBAyGIQMBiGDQchgEDIYhAwGIYNB
yGAQMhiEDAYhg0HIYBAyGIQMBiGDQchgEDIYhAwGIYNByGAQMhiEDAYhg0HIYBAy
GIQMBiGDQchgEDIYhAwGIYNByGAQMhiELvqcclohBiIOAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(0,-.34391699,.34840066,0,59.53476,105.97824)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAASEAAABQCAIAAADZdlScAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAA/ElEQVR4nO3TUQkAIBTAwNc/m1HsoCmGIAcXYD+btQ/QmecF8DeP
Qctj0PIYtDwGLY9By2PQ8hi0PAYtj0HLY9DyGLQ8Bi2PQctj0PIYtDwGLY9By2PQ
8hi0PAYtj0HLY9DyGLQ8Bi2PQctj0PIYtDwGLY9By2PQ8hi0PAYtj0HLY9DyGLQ8
Bi2PQctj0PIYtDwGLY9By2PQ8hi0PAYtj0HLY9DyGLQ8Bi2PQctj0PIYtDwGLY9B
y2PQ8hi0PAYtj0HLY9DyGLQ8Bi2PQctj0PIYtDwGLY9By2PQ8hi0PAYtj0HLY9Dy
GLQ8Bi2PQctj0PIYtDwGLY9By2PQur1VPYy2nYZ+AAAAAElFTkSuQmCC">
<p style="top:436.1pt;left:51.1pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">FigURe 1 </span></b><span style="font-family:Arial,serif;font-size:7.0pt">| Flow diagram of the screening process. RCT, randomized controlled trial; TBI, traumatic brain injury.</span></p>
<p style="top:741.9pt;left:294.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">6</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>
<p style="top:472.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">experiments (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">41</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">50</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">55</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). In some experiments, other agents </span></p>
<p style="top:483.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">such as selenium (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">47</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), 2,4-disulfonyl </span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&#x3b1;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">-phenyl tertiary butyl </span></p>
<p style="top:495.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">nitrone (HPN-07) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">39</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), topiramate (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), and minocycline (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">44</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) </span></p>
<p style="top:506.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">were used in combination with NAC. NACA, the BBB permeable </span></p>
<p style="top:518.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">derivative of NAC, was provided in three experiments (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">43</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">46</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">48</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). </span></p>
<p style="top:529.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The route of administration in 17 studies (18 experiments) was </span></p>
<p style="top:541.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">intraperitoneal (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">37</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">46</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">48</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">50</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">55</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) and the drug was delivered </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">via</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt"> </span></p>
<p style="top:552.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">injection immediately after or up to 2&#xa0;h post-injury (median 1&#xa0;h). </span></p>
<p style="top:564.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Subsequent doses were given in 16 studies, usually up to 48&#x2013;72&#xa0;h </span></p>
<p style="top:575.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of the injury (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">37</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">42</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">44</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">46</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">52</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">54</span><span style="font-family:MinionPro,serif;font-size:9.5pt">).</span></p>
<p style="top:596.9pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Risk of Bias</span></b></p>
<p style="top:610.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Only the RCT conducted on military personnel following blast </span></p>
<p style="top:621.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">35</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) had an appropriate design and sample size calculation </span></p>
<p style="top:633.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">required to detect differences between treatment groups (</span><b><span style="font-family:MinionPro,serif;font-size:9.5pt">Tables&#xa0;4</span></b><span style="font-family:MinionPro,serif;font-size:9.5pt"> </span></p>
<p style="top:644.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and </span><b><span style="font-family:MinionPro,serif;font-size:9.5pt">5</span></b><span style="font-family:MinionPro,serif;font-size:9.5pt">). The pediatric RCT (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">36</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), though well controlled, had a </span></p>
<p style="top:656.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">small sample size of 14 patients and no sample size calculation </span></p>
<p style="top:667.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">was reported. Finally, the study conducted in retired professional </span></p>
<p style="top:679.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">athletes (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">34</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) was non-randomized, self-matched, and unblinded. </span></p>
<p style="top:690.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">This study reported limited information concerning attrition, the </span></p>
<p style="top:702.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">NAC regimen used, leading to a high risk of experimental bias.</span></p>
<p style="top:472.4pt;left:317.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Ten animal studies had a random sequence of allocation (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span></p>
<p style="top:483.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">38</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">42</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">43</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">45</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">47</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">48</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">51</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) and only 1 of them had allocation </span></p>
<p style="top:495.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">concealment and blinding (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">48</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Other limitations of some studies </span></p>
<p style="top:506.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">included lack of reporting animal inclusion criteria, sample size </span></p>
<p style="top:518.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">calculation, and reporting of outcomes. For detailed information </span></p>
<p style="top:529.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">on each domain, please see </span><b><span style="font-family:MinionPro,serif;font-size:9.5pt">Table&#xa0;5</span></b><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:550.9pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Outcomes</span></b></p>
<p style="top:564.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">Neurofunctional Status&#x2014;Human Studies</span></p>
<p style="top:576.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The RCT conducted on military personnel (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">35</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) showed sig-</span></p>
<p style="top:587.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">nificant improvements in TBI symptoms, such as imbalance </span></p>
<p style="top:599.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and headache, both assessed on day 7 in the treatment group </span></p>
<p style="top:610.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">compared to the placebo group (odds ratio 3.6, </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt"> =</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0; 0.006). </span></p>
<p style="top:622.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The authors demonstrated that the proportion of symptom </span></p>
<p style="top:633.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">improvements was about 86% in those who were treated earlier </span></p>
<p style="top:645.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">with NAC (i.e., within 24&#xa0;h post injury) as compared to 46% </span></p>
<p style="top:656.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in those who received the drug between 24 and 72 hours. </span></p>
<p style="top:668.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Significant improvements were from baseline values in NAC </span></p>
<p style="top:679.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">treated patients for trail making tasks A [</span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">F</span></i><span style="font-family:MinionPro,serif;font-size:5.5pt">(1,74)</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;6.64, </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&lt;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.05] </span></p>
<p style="top:691.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and B [</span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">F</span></i><span style="font-family:MinionPro,serif;font-size:5.5pt">(1,74)</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;4.87, </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&lt;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.05]. Similar significant improvements </span></p>
<p style="top:702.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">were not seen in the placebo group. No significant differences </span></p>


<p style="top:61.5pt;left:45.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">taBle 3</span></b><span style="font-family:Arial,serif;font-size:7.0pt"> | Outcome measures and summary of findings in 20 animal studies (21 experiments).</span></p>
<p style="top:78.1pt;left:45.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Reference</span></b></p>
<p style="top:78.1pt;left:118.5pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Outcome(s) measured</span></b></p>
<p style="top:78.1pt;left:262.7pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Summary of findings in </span></b><b><i><span style="font-family:Arial,serif;font-size:7.0pt">N-</span></i></b><b><span style="font-family:Arial,serif;font-size:7.0pt">acetylcysteine treated animals compared to controls</span></b></p>
<p style="top:95.1pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Abdel-Baki et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">37</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:95.1pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Variants of place avoidance task (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">56</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:95.4pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 NAC&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;minocycline: improvement of active place avoidance (F</span><span style="font-family:Arial,serif;font-size:4.1pt">4,25</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">=</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;34.68; </span><i><span style="font-family:Arial,serif;font-size:7.0pt">p</span></i><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">=</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;0.01).</span></p>
<p style="top:109.0pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Chen et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">38</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:109.0pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NH-kB; IL-1</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">&#x3b2;</span><span style="font-family:Arial,serif;font-size:7.0pt">; TNF-</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">&#x3b1;</span><span style="font-family:Arial,serif;font-size:7.0pt">; IL-6; ICAM-1 micro-</span></p>
<p style="top:118.5pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">vessels; brain water; BBB; cell apoptosis</span></p>
<p style="top:109.0pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 NF-kB, UL-1</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">&#x3b2;</span><span style="font-family:Arial,serif;font-size:7.0pt">, IL-6, TNF-</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">&#x3b1;</span><span style="font-family:Arial,serif;font-size:7.0pt">, ICAM-1: upregulated following TBI and suppressed with NAC</span></p>
<p style="top:118.5pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 NAC: </span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">&#x2193;</span><span style="font-family:Arial,serif;font-size:7.0pt"> Brain edema, barrier permeability, and apoptosis</span></p>
<p style="top:132.1pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Du et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">39</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:132.1pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">4-HNE; c-fos; amyloid beta (A4); APP; GFAP; </span></p>
<p style="top:141.6pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">NF-68; caspase 3</span></p>
<p style="top:132.1pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 Blast exposure: upregulated 4-HNE, c-fos, GFAP, APP, and HNF 68</span></p>
<p style="top:141.6pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 NAC: reduced the levels of all biomarkers in specific brain areas</span></p>
<p style="top:155.2pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Eakin et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">40</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:155.2pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">MWM: hidden platform, probe trial, visible </span></p>
<p style="top:164.7pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">platform</span></p>
<p style="top:155.2pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1  Treatment group: Improved performance in MWM tasks, probe trial, and visible platform </span></p>
<p style="top:164.7pt;left:272.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">tasks (</span><i><span style="font-family:Arial,serif;font-size:7.0pt">p</span></i><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">&lt;</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;0.05)</span></p>
<p style="top:178.3pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Eakin et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">40</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:178.3pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Novel object recognition; Y maze paradigm</span></p>
<p style="top:178.3pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1  Treatment group: significantly improved performance for both tasks (</span><i><span style="font-family:Arial,serif;font-size:7.0pt">p</span></i><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">&lt;</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;0.05)</span></p>
<p style="top:192.0pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Ellis et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">41</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:192.0pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Mean arterial pressure</span></p>
<p style="top:192.0pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1  Cats receiving NAC demonstrated vasoconstriction (one of mechanism involved in oxidative </span></p>
<p style="top:201.5pt;left:272.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">stress)</span></p>
<p style="top:215.1pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Ewert et&#xa0;al., (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">42</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:215.1pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">ABR; DPOE level shifts; hair cell loss on </span></p>
<p style="top:224.6pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">cochlear histology</span></p>
<p style="top:215.1pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 ABR threshold was 10&#xa0;dB less at 24&#xa0;h. Difference in thresholds was around 20&#xa0;dB at 7 and </span></p>
<p style="top:224.6pt;left:272.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">21&#xa0;days between the treated and control group</span></p>
<p style="top:234.1pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 DPOE levels shift recovered around 7d in treated group</span></p>
<p style="top:243.6pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 3 Hair cell loss was significantly less in treated group</span></p>
<p style="top:257.2pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Gunther et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">43</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:257.2pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Fluro-Jade B; TUNEL; MnSOD; Ox-42; iNOS; </span></p>
<p style="top:266.7pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">3-NT; NFkB; Caspase 3; Cytochrome C; bcl-</span></p>
<p style="top:276.2pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2; Cy3; Alexa 488; Biotinyl</span></p>
<p style="top:257.2pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 Significant lower levels of necrotic cell death and apoptosis</span></p>
<p style="top:266.7pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 Levels of antioxidant enzyme MnSOD were significantly higher</span></p>
<p style="top:289.8pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Haber et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">44</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:289.8pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Four variants of place avoidance tasks (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">56</span><span style="font-family:Arial,serif;font-size:7.0pt">). </span></p>
<p style="top:299.3pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Brain sections of injured area</span></p>
<p style="top:289.8pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 NAC&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;minocycline: performed better on conflict active place avoidance task and limited </span></p>
<p style="top:299.3pt;left:272.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">memory deficits</span></p>
<p style="top:308.8pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 NAC&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;minocycline: associated with decreased CD68 expression and increased microglial </span></p>
<p style="top:318.3pt;left:272.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">activation.</span></p>
<p style="top:332.0pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Hicdonmez et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">45</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:332.0pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">MDA; SOD activity; GPx activity; catalase </span></p>
<p style="top:341.5pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">activity</span></p>
<p style="top:351.0pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Number of neurons (/mm</span><sup><span style="font-family:Arial,serif;font-size:4.1pt">2</span></sup><span style="font-family:Arial,serif;font-size:7.0pt">); caspase 3 activity</span></p>
<p style="top:332.0pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 Treatment group: significant increased activity of SOD and GPx at 12&#xa0;h</span></p>
<p style="top:341.5pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 Treatment group: significant GPx activity at 2&#xa0;h</span></p>
<p style="top:351.0pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 3 Morphology of neurons was well protected in the NAC group</span></p>
<p style="top:364.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Kawoos et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">46</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:364.6pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Intracranial pressure monitoring</span></p>
<p style="top:364.6pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 Single NACA dose reduced ICP after single BOP induced injury</span></p>
<p style="top:374.1pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 Single NACA dose was not effective in reducing ICP after multiple BOP</span></p>
<p style="top:383.6pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 3 Two NACA doses were effective in reducing ICP after multiple BOP</span></p>
<p style="top:393.1pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 4 A pre-injury NACA dose was most effective in reducing ICP after multiple BOP</span></p>
<p style="top:406.7pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Naziroglu et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">47</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:406.7pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Intracellular Ca</span><sup><span style="font-family:Arial,serif;font-size:4.1pt">2</span></sup><sup><span style="font-family:STIXGeneral,serif;font-size:4.1pt">+</span></sup><span style="font-family:Arial,serif;font-size:7.0pt">; apoptosis; caspase activity, </span></p>
<p style="top:416.2pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">and ROS in hippocampal cells</span></p>
<p style="top:406.7pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 NAC group: </span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">&#x2193;</span><span style="font-family:Arial,serif;font-size:7.0pt"> Intracellular free Ca</span><sup><span style="font-family:Arial,serif;font-size:4.1pt">2</span></sup><sup><span style="font-family:STIXGeneral,serif;font-size:4.1pt">+</span></sup><span style="font-family:Arial,serif;font-size:7.0pt">, apoptosis, caspase 3 and 9 activity, and ROS levels</span></p>
<p style="top:416.2pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 Se group: some effect, but NAC group had a much greater effect</span></p>
<p style="top:429.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Pandya et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">48</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:429.9pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Exp 1&#x2014;tissue sparing; Exp 2&#x2014;oxidative </span></p>
<p style="top:439.4pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">stress; Exp 3&#x2014;mitochondrial bioenergetics </span></p>
<p style="top:448.9pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">and glutathione content; Exp 1&#x2013;3 cognitive </span></p>
<p style="top:458.4pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">behavioral assessment</span></p>
<p style="top:429.9pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 NACA: better than NAC for tissue sparing and cognitive behavior.</span></p>
<p style="top:439.4pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 NACA: </span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">&#x2193;</span><span style="font-family:Arial,serif;font-size:7.0pt"> oxidative stress, improved mitochondrial bioenergetics, and maintenance of GSH</span></p>
<p style="top:472.0pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Senol et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">20</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:472.0pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Lipid peroxidation; GSH; GSH peroxidase; </span></p>
<p style="top:481.5pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">protein assay; brain cortex </span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">&#x3b2;</span><span style="font-family:Arial,serif;font-size:7.0pt">-Carotene, </span></p>
<p style="top:491.0pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Vitamins A, C, and E</span></p>
<p style="top:472.0pt;left:262.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 NAC group: significantly higher levels of GSH, Vitamin A, Vitamin E, and total oxidant status</span></p>
<p style="top:504.6pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Silva et&#xa0;al., (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">49</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:504.6pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Drug induced seizures; Na&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;K&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;ATPase </span></p>
<p style="top:514.1pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">activity; TBAR; protein carbonyl</span></p>
<p style="top:504.6pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 NAC group: more protection from drug induced seizures and Na&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;, K&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;ATPase inhibition</span></p>
<p style="top:527.7pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Thomale et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">50</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:527.7pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Brain edema, ABG; ICP; contusion volume</span></p>
<p style="top:527.7pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No differences were observed</span></p>
<p style="top:541.4pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Thomale et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">51</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:541.4pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">MAP; ABG; CBF; ICP; water content; </span></p>
<p style="top:550.9pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">contusion volume</span></p>
<p style="top:541.4pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No differences were observed</span></p>
<p style="top:564.5pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Xiong et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">52</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:564.5pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Mitochondrial activity; Ca&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:7.0pt">+</span><span style="font-family:Arial,serif;font-size:7.0pt">&#xa0;2 content and </span></p>
<p style="top:574.0pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">transport; GSH</span></p>
<p style="top:564.5pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 NAC: significant impact on mitochondrial bioenergetics and Ca uptake</span></p>
<p style="top:574.0pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 NAC: restored GSH levels during the 14-day observation period</span></p>
<p style="top:587.6pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Xiong et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">53</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:587.6pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Apoptosis-related proteins; shortened bcl-2 </span></p>
<p style="top:597.1pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">and Bax; cytochrome c</span></p>
<p style="top:587.6pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 NAC: diminished levels of shortened bcl-2 and Bax</span></p>
<p style="top:610.7pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yi and Hazell (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">54</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:610.7pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">HO-1 activity in specific brain regions; volume </span></p>
<p style="top:620.2pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">of injury</span></p>
<p style="top:610.7pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 NAC: lower levels of HO-1 in cerebral cortex, thalamus, and hippocampus</span></p>
<p style="top:620.2pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 NAC: associated with significantly decreased volume of injury</span></p>
<p style="top:633.9pt;left:45.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yi et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">55</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:633.9pt;left:118.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Complexin I and II; neuronal cell loss</span></p>
<p style="top:633.9pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 1 NAC: reversed increased in Complexin levels in the injured cortex</span></p>
<p style="top:643.4pt;left:262.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt"> 2 NAC: significantly less neuronal cell loss</span></p>
<p style="top:659.1pt;left:45.4pt;line-height:6.5pt"><i><span style="font-family:Arial,serif;font-size:6.5pt">HNE, 4-hydroxy-2-nonenal; SOD, superoxide dismutase; ABG, arterial blood gas; ABR, auditory brain stem; BB, blood&#x2013;brain barrier; BOP, blast overpressure; CBF, cerebral blood </span></i></p>
<p style="top:668.1pt;left:45.4pt;line-height:6.5pt"><i><span style="font-family:Arial,serif;font-size:6.5pt">flow; c-fos, genetic biomarker; COWA, controlled oral word association test; DPOE, distortion product optoacoustic emissions; GPx, glutathione peroxidase; HO-1, hemeoxygenase </span></i></p>
<p style="top:677.1pt;left:45.4pt;line-height:6.5pt"><i><span style="font-family:Arial,serif;font-size:6.5pt">-1; ICP, intracranial pressure; ICAM, intercellular adhesion Molecule-1; IL-1</span></i><span style="font-family:STIXGeneral,serif;font-size:6.5pt">&#x3b2;</span><i><span style="font-family:Arial,serif;font-size:6.5pt">, interleukin 1-beta; IL-6, interleukin 6; MPO, myeloperoxidase; MDA, melandialdehyde; NAC, </span></i></p>
<p style="top:686.1pt;left:45.4pt;line-height:6.5pt"><i><span style="font-family:Arial,serif;font-size:6.5pt">N-acetylcysteine; NACA, N-acetylcysteine amide; NH-kB, nuclear factor kappa B; ROS, reactive oxygen species; Se, selenium; SOD, superoxide dismutase; TBAR, thiobarbituric </span></i></p>
<p style="top:695.1pt;left:45.4pt;line-height:6.5pt"><i><span style="font-family:Arial,serif;font-size:6.5pt">acid reactive substances; TBI, traumatic brain injury; TNF-</span></i><span style="font-family:STIXGeneral,serif;font-size:6.5pt">&#x3b1;</span><i><span style="font-family:Arial,serif;font-size:6.5pt">, tumor necrosis factor alpha.</span></i></p>
<p style="top:741.9pt;left:294.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">7</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>


<p style="top:741.9pt;left:294.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">8</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>
<p style="top:61.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">were observed in hearing loss and memory problems between </span></p>
<p style="top:72.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">the NAC treated and the placebo group on day 7. The study </span></p>
<p style="top:84.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">on retired professional football players (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">34</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) showed significant </span></p>
<p style="top:95.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">improvements compared to their baseline measures in overall </span></p>
<p style="top:107.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cognitive functioning (mean&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;43 vs. 32, </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&lt;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.001), cognitive </span></p>
<p style="top:118.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">proficiency (mean score&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;35 vs. 25, </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&lt;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.001), processing speed </span></p>
<p style="top:130.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(mean score&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;39 vs. 33, </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&lt;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.001), processing accuracy (mean </span></p>
<p style="top:141.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">score&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;49 vs. 41, </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.01), attention (mean score&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;49 vs. 41, </span></p>
<p style="top:153.4pt;left:45.4pt;line-height:9.5pt"><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.01), reasoning (mean score&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;42 vs. 33, </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&lt;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.01), and </span></p>
<p style="top:164.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">memory (mean score&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;43 vs. 34, </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.02). Improvements in </span></p>
<p style="top:176.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cognitive functioning were associated with significant improve-</span></p>
<p style="top:187.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ments in the brain perfusion (</span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&lt;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.001) in specific brain regions </span></p>
<p style="top:199.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in the prefrontal, orbital, parietal, and occipital cortices. A recent </span></p>
<p style="top:211.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">phase 1 RCT conducted in 14 pediatric patients (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">36</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) reported no </span></p>
<p style="top:222.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">difference in the Glasgow outcome scale recorded upon hospital </span></p>
<p style="top:234.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">discharge or at three months follow-up.</span></p>
<p style="top:256.5pt;left:45.4pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">Neurofunctional Status&#x2014;Animal Studies</span></p>
<p style="top:268.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">As compared to controls, animals treated with NAC showed sig-</span></p>
<p style="top:279.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">nificant improvements in specific neurocognitive and psychomo-</span></p>
<p style="top:291.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tor tasks (</span><b><span style="font-family:MinionPro,serif;font-size:9.5pt">Table&#xa0;3</span></b><span style="font-family:MinionPro,serif;font-size:9.5pt">). These tasks included active place avoidance </span></p>
<p style="top:302.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(spatial memory) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">37</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), novel object recognition (memory) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), </span></p>
<p style="top:314.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Y-maze (spatial memory) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), probe trial (learning) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), and </span></p>
<p style="top:325.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">visible platform tasks (visual acuity and motor ability) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). In </span></p>
<p style="top:337.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">a study conducted in rats with moderate TBI (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">44</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) where NAC </span></p>
<p style="top:348.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">use was associated with minocycline, authors concluded that </span></p>
<p style="top:360.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">there was a possible synergy between the two drugs, leading to </span></p>
<p style="top:371.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">improvement of long-term memory and set-shifting, compared </span></p>
<p style="top:383.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">to controls. In another study where NACA was used (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">48</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), </span></p>
<p style="top:394.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">improvements in the acquisition phase of the Morris Water </span></p>
<p style="top:406.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Maze task (spatial learning and memory) were demonstrated, </span></p>
<p style="top:418.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">compared to controls. Furthermore, NAC protected against hair </span></p>
<p style="top:429.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cell loss that caused subsequent hearing impairment in another </span></p>
<p style="top:441.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">study (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">42</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). The effect of NAC on seizure disorder following TBI </span></p>
<p style="top:452.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">was addressed in a study with Wistar rats (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">49</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) and reported a </span></p>
<p style="top:464.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">reduced risk for pentylenetetrazol-induced seizures, compared </span></p>
<p style="top:475.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">to controls.</span></p>
<p style="top:498.0pt;left:45.4pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">Biological Markers&#x2014;Human Studies</span></p>
<p style="top:509.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">In the most recent phase 1 RCT conducted in 14 pediatric </span></p>
<p style="top:521.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">patients (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">36</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), which evaluated the use of NAC and probenecid </span></p>
<p style="top:532.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(pro-NAC), it was reported increased levels of both drugs in the </span></p>
<p style="top:544.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cerebrospinal fluid of patients in the intervention group. The </span></p>
<p style="top:555.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">authors also measured levels of serum neuro-injury biomarkers, </span></p>
<p style="top:567.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">such as the Neuron Specific Enolase (NSE) and the Glial Fibrillary </span></p>
<p style="top:578.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Acidic Protein (GFAP); however, levels of these biomarkers were </span></p>
<p style="top:590.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">not different between the intervention and control groups (NSE </span></p>
<p style="top:601.9pt;left:45.4pt;line-height:9.5pt"><i><span style="font-family:MinionPro,serif;font-size:9.5pt">F</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">[1,45]&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.60, </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.441 and GFAP </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">F</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">[1,45]&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.29, </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">=</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.596, </span></p>
<p style="top:613.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">respectively).</span></p>
<p style="top:636.0pt;left:45.4pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">Biological Markers&#x2014;Animal Studies</span></p>
<p style="top:647.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Recent animal experiments have focused on assessing the effects </span></p>
<p style="top:659.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of NAC administration on levels of several oxidative stress </span></p>
<p style="top:670.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">biomarkers and glutathione (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">48</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) (</span><b><span style="font-family:MinionPro,serif;font-size:9.5pt">Table&#xa0;3</span></b><span style="font-family:MinionPro,serif;font-size:9.5pt">). For example, several </span></p>
<p style="top:682.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">studies indicate better mitochondrial respiration and a higher </span></p>
<p style="top:693.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">glutathione content in animals with brain injury treated with </span></p>
<p style="top:705.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">NAC, compared to controls (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">48</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">52</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">53</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Treatment with NAC </span></p>
<p style="top:61.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">was also associated with lower levels of IL-1</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&#x3b2;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2014;a potent pyrogenic </span></p>
<p style="top:73.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cytokine protein, nuclear factor (NF)-</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&#x3ba;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">B&#x2014;prominent transcrip-</span></p>
<p style="top:84.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tion factor that regulates inflammation and cellular survival, </span></p>
<p style="top:96.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">TNF-</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&#x3b1;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2014;prototypical pro-inflammatory cytokine, IL-6&#x2014;a key </span></p>
<p style="top:107.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">inflammatory and immunoregulatory cytokine, intercellular </span></p>
<p style="top:119.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">adhesion molecule-1&#x2014;early adhesion protein that promotes </span></p>
<p style="top:130.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">leukocyte transmigration, 4-hydroxy-2-nonenal (4-HNE)&#x2014;a </span></p>
<p style="top:142.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">marker of oxidative stress, c-fos&#x2014;an immediate gene expressed </span></p>
<p style="top:153.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in cell proliferation, regulation, and survival, GFAP&#x2014;an astrocyte </span></p>
<p style="top:165.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">injury marker, the beta-amyloid precursor protein (</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&#x3b2;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">-APP)&#x2014;a </span></p>
<p style="top:176.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">marker of chronic axonal damage, and neurofilament light&#x2014;</span></p>
<p style="top:188.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">also a key marker of axonal injury (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">38</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">39</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Other studies have </span></p>
<p style="top:199.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">demonstrated improvements in makers known to modulate the </span></p>
<p style="top:211.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">oxidative stress, such as in apoptosis-related proteins [B-cell </span></p>
<p style="top:222.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">lymphoma-2 (bcl-2) protein and bcl-2-associated X protein </span></p>
<p style="top:234.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(Bax)] (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">53</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), in a protein involved in the oxidative stress cascade </span></p>
<p style="top:245.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">[hemeoxygenase-1 (HO-1)], and in membrane proteins involved </span></p>
<p style="top:257.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in neurotransmission (Complexin I and II) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">55</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Combined </span></p>
<p style="top:268.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">administration of NAC and Selenium was associated with reduc-</span></p>
<p style="top:280.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tions in cytosolic-free Ca</span><sup><span style="font-family:STIXGeneral,serif;font-size:5.5pt">++</span></sup><span style="font-family:MinionPro,serif;font-size:9.5pt">, apoptosis, cytosolic ROS, capsace-3, </span></p>
<p style="top:291.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and capsace-9 (proteases responsible for the disassembly of the </span></p>
<p style="top:303.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cell into apoptotic bodies), lipid peroxidation, total oxidant </span></p>
<p style="top:314.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">status, plasma IL-1</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&#x3b2;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, and plasma IL-4 activities in rats inflicted </span></p>
<p style="top:326.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">with moderate TBI, as compared to untreated controls (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">20</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">47</span><span style="font-family:MinionPro,serif;font-size:9.5pt">).</span></p>
<p style="top:337.6pt;left:317.6pt;line-height:9.5pt"><i><span style="font-family:MinionPro,serif;font-size:9.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">-Acetylcysteine amide has been used in three animal studies </span></p>
<p style="top:349.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">43</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">46</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">48</span><span style="font-family:MinionPro,serif;font-size:9.5pt">); two of which, examined biomarkers (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">43</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">48</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) and one </span></p>
<p style="top:360.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">that reported its effect on ICP levels (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">46</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Significant reductions </span></p>
<p style="top:372.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in Fluoro-Jade (a marker of neuronal degeneration) and terminal </span></p>
<p style="top:383.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">deoxynucleotidyl transferase dUTP nick end labeling (TUNEL, a </span></p>
<p style="top:395.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">marker of apoptosis) were documented in Sprague&#x2013;Dawley rats </span></p>
<p style="top:406.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">subjected to moderate TBI (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">43</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). The authors also demonstrated </span></p>
<p style="top:418.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">an increase in Manganese superoxide dismutase (MnSOD, an </span></p>
<p style="top:429.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">antioxidant enzyme) relative to controls (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">43</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). In another study </span></p>
<p style="top:441.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">48</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), the use of NACA was associated with improvement of </span></p>
<p style="top:452.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mitochondrial bioenergetics, glutathione content, cortical spar-</span></p>
<p style="top:464.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ing, and reduced HNE levels.</span></p>
<p style="top:485.1pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Other Secondary Outcomes Reported</span></b></p>
<p style="top:498.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Six studies (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">38</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">41</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">46</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">50</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">51</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">54</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) assessed other secondary </span></p>
<p style="top:510.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">outcomes, such as the size of brain contusion, vasoconstriction </span></p>
<p style="top:521.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">or dilatation, ICP, edema, or imaging (</span><b><span style="font-family:MinionPro,serif;font-size:9.5pt">Table&#xa0;3</span></b><span style="font-family:MinionPro,serif;font-size:9.5pt">). For example, in </span></p>
<p style="top:533.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">a study conducted in rats, use of NAC showed a non-significant </span></p>
<p style="top:544.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">decrease of 19% in contusion volume compared to untreated </span></p>
<p style="top:556.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">brains, as morphometrically measured using slice staining and </span></p>
<p style="top:567.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">imaging (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">50</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). The same investigators noted in another study with </span></p>
<p style="top:579.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">a larger sample size, that NAC treatment has no significant impact </span></p>
<p style="top:590.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">on ICP or water content (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">51</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Similarly, the administration of </span></p>
<p style="top:602.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">NAC had no effects on cerebrovascular responsiveness as meas-</span></p>
<p style="top:613.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ured by intra-arterial pressure in brain vessels (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">41</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). At the cellular </span></p>
<p style="top:625.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">level, brain injury models where NAC was used for treatment, </span></p>
<p style="top:636.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">showed decreased brain edema, BBB permeability, and apoptotic </span></p>
<p style="top:648.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cell death compared to untreated brains (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">38</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Lastly, in a recent </span></p>
<p style="top:659.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">study, NACA significantly reduced the ICP in rats sustaining </span></p>
<p style="top:671.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">single and multiple injuries (two-way repeated measure ANOVA </span></p>
<p style="top:682.7pt;left:306.1pt;line-height:9.5pt"><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&lt;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.05) (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">46</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). This study found that pre-injury and repeated </span></p>
<p style="top:694.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doses of NACA were dose-dependently effective in reducing ICP </span></p>
<p style="top:705.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">after TBI (two-way repeated measure ANOVA </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">p</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;</span><span style="font-family:STIXGeneral,serif;font-size:9.5pt">&lt;</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#xa0;0.05).</span></p>


<p style="top:61.5pt;left:45.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">taBle 4</span></b><span style="font-family:Arial,serif;font-size:7.0pt"> | Risk of bias in human trials assessing the role of </span><i><span style="font-family:Arial,serif;font-size:7.0pt">N</span></i><span style="font-family:Arial,serif;font-size:7.0pt">-acetylcysteine for traumatic brain injuries.</span></p>
<p style="top:78.1pt;left:128.9pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Selection bias</span></b></p>
<p style="top:78.1pt;left:214.1pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Performance </span></b></p>
<p style="top:87.6pt;left:228.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">bias</span></b></p>
<p style="top:78.1pt;left:278.0pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Detection bias</span></b></p>
<p style="top:78.1pt;left:347.7pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">attrition bias</span></b></p>
<p style="top:78.1pt;left:407.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Reporting bias</span></b></p>
<p style="top:78.1pt;left:492.5pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Other bias</span></b></p>
<p style="top:104.6pt;left:105.2pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Random </span></b></p>
<p style="top:114.1pt;left:105.2pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">sequence </span></b></p>
<p style="top:123.6pt;left:105.2pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">generation</span></b></p>
<p style="top:104.6pt;left:155.2pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">allocation </span></b></p>
<p style="top:114.1pt;left:155.2pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">concealment</span></b></p>
<p style="top:140.6pt;left:45.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">amen et&#xa0;al. (34)</span></b></p>
<p style="top:150.1pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Ranking</span></p>
<p style="top:150.1pt;left:105.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">High-risk</span></p>
<p style="top:150.1pt;left:155.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">High-risk</span></p>
<p style="top:150.1pt;left:211.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">High-risk</span></p>
<p style="top:150.1pt;left:272.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Unclear</span></p>
<p style="top:150.1pt;left:344.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Unclear</span></p>
<p style="top:150.1pt;left:405.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">High-risk</span></p>
<p style="top:150.1pt;left:469.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">High-risk</span></p>
<p style="top:159.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Explanation</span></p>
<p style="top:159.6pt;left:105.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Not </span></p>
<p style="top:169.1pt;left:105.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">randomized</span></p>
<p style="top:159.6pt;left:155.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No allocation </span></p>
<p style="top:169.1pt;left:155.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">concealment</span></p>
<p style="top:159.6pt;left:211.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No blinding</span></p>
<p style="top:159.6pt;left:272.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No information </span></p>
<p style="top:169.1pt;left:272.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">provided</span></p>
<p style="top:159.6pt;left:344.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No information </span></p>
<p style="top:169.1pt;left:344.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">provided</span></p>
<p style="top:159.6pt;left:405.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Selective results </span></p>
<p style="top:169.1pt;left:405.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">presented</span></p>
<p style="top:159.6pt;left:469.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Other drugs used, no </span></p>
<p style="top:169.1pt;left:469.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">dosage, compliance not </span></p>
<p style="top:178.6pt;left:469.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">reported </span></p>
<p style="top:192.2pt;left:45.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Hoffer et&#xa0;al. (35)</span></b></p>
<p style="top:201.7pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Ranking</span></p>
<p style="top:201.7pt;left:105.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Low-risk</span></p>
<p style="top:201.7pt;left:155.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Low-risk</span></p>
<p style="top:201.7pt;left:211.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Low-risk</span></p>
<p style="top:201.7pt;left:272.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Low-risk</span></p>
<p style="top:201.7pt;left:344.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Low-risk</span></p>
<p style="top:201.7pt;left:405.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Low-risk</span></p>
<p style="top:201.7pt;left:469.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">High-risk</span></p>
<p style="top:211.2pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Explanation</span></p>
<p style="top:211.2pt;left:105.2pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Randomized</span></p>
<p style="top:211.2pt;left:155.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Allocation </span></p>
<p style="top:220.7pt;left:155.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">concealment </span></p>
<p style="top:230.2pt;left:155.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">done</span></p>
<p style="top:211.2pt;left:211.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Blinding of </span></p>
<p style="top:220.7pt;left:211.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">participants and </span></p>
<p style="top:230.2pt;left:211.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">assessors</span></p>
<p style="top:211.2pt;left:272.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Blinding of outcome </span></p>
<p style="top:220.7pt;left:272.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">assessor</span></p>
<p style="top:211.2pt;left:344.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">All subjects </span></p>
<p style="top:220.7pt;left:344.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">followed to </span></p>
<p style="top:230.2pt;left:344.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">endpoint</span></p>
<p style="top:211.2pt;left:405.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Trial protocol and </span></p>
<p style="top:220.7pt;left:405.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">study reported</span></p>
<p style="top:211.2pt;left:469.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Generalizable? (conducted </span></p>
<p style="top:220.7pt;left:469.7pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">in the military setting)</span></p>
<p style="top:243.8pt;left:45.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">clark et&#xa0;al. (36)</span></b></p>
<p style="top:253.3pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Ranking</span></p>
<p style="top:253.3pt;left:105.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Low-risk</span></p>
<p style="top:253.3pt;left:155.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Unclear</span></p>
<p style="top:253.3pt;left:211.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Low-risk</span></p>
<p style="top:253.3pt;left:272.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Low-risk</span></p>
<p style="top:253.3pt;left:344.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Low-risk</span></p>
<p style="top:253.3pt;left:405.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Low-risk</span></p>
<p style="top:253.3pt;left:469.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">High-risk</span></p>
<p style="top:262.8pt;left:45.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Explanation</span></p>
<p style="top:262.8pt;left:105.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Randomized</span></p>
<p style="top:262.8pt;left:155.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No information </span></p>
<p style="top:272.3pt;left:155.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">provided</span></p>
<p style="top:262.8pt;left:211.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Blinding of </span></p>
<p style="top:272.3pt;left:211.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">participants and </span></p>
<p style="top:281.8pt;left:211.6pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">assessors</span></p>
<p style="top:262.8pt;left:272.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Blinding of outcome </span></p>
<p style="top:272.3pt;left:272.1pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">assessor</span></p>
<p style="top:262.8pt;left:344.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">All subjects </span></p>
<p style="top:272.3pt;left:344.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">were followed to </span></p>
<p style="top:281.8pt;left:344.5pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">endpoint</span></p>
<p style="top:262.8pt;left:405.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Reported prior </span></p>
<p style="top:272.3pt;left:405.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">publication in </span></p>
<p style="top:281.8pt;left:405.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">clinicaltrials.gov</span></p>
<p style="top:262.8pt;left:469.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Small sample size</span></p>
<p style="top:741.9pt;left:294.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">9</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>
<p style="top:324.0pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">adverse events</span></b></p>
<p style="top:337.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">No drug-attributable safety events were reported in any of the </span></p>
<p style="top:349.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">TBI studies cited. This conclusion is consistent with previous </span></p>
<p style="top:360.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">literature reports on the use of NAC for other medical condi-</span></p>
<p style="top:372.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tions and as a potential performance enhancing ergogenic aid </span></p>
<p style="top:383.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">67</span><span style="font-family:MinionPro,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">69</span><span style="font-family:MinionPro,serif;font-size:9.5pt">).</span></p>
<p style="top:404.5pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">combined therapies</span></b></p>
<p style="top:418.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The association of NAC with other drugs has demonstrated a </span></p>
<p style="top:429.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">potential synergistic effect in four animal studies included in </span></p>
<p style="top:441.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">this review (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">39</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">42</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">44</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Probenecid, well known to augment </span></p>
<p style="top:452.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">the systemic exposure of antimicrobial agents </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">via</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt"> inhibition </span></p>
<p style="top:464.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of drug elimination through membrane transporters, can </span></p>
<p style="top:475.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">also prevent intracellular depletion of GSH (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">70</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). The study in </span></p>
<p style="top:487.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">children with severe TBI (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">36</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) has demonstrated that the co-</span></p>
<p style="top:498.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">administration of probenecid increases NAC concentration in </span></p>
<p style="top:510.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">both the brain and plasma, thus offering additive mechanisms </span></p>
<p style="top:521.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">for therapeutic synergy. In an animal model of blast injury (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">42</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) </span></p>
<p style="top:533.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">that produced auditory damage as primary sequela, a combina-</span></p>
<p style="top:544.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tion of an antioxidant (2,4-disulfonyl a-phenyl tertiary butyl </span></p>
<p style="top:556.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">nitrone [HPN-07]) and NAC could both enhance temporary </span></p>
<p style="top:567.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">auditory recovery and prevent permanent cellular damage </span></p>
<p style="top:579.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">when administered early post-blast exposure. The association </span></p>
<p style="top:590.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of minocycline and NAC in a model of mild TBI (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">44</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) lead to </span></p>
<p style="top:602.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">a regulation of inflammation at tissue level (i.e., modulation of </span></p>
<p style="top:613.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">microglia), which may be an additional site of drug synergy </span></p>
<p style="top:625.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">between minocycline and NAC since microglial cell activation </span></p>
<p style="top:636.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">is known to be redox-regulated. Lastly, another experimental </span></p>
<p style="top:648.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">study where topiramate was administered in association with </span></p>
<p style="top:659.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">NAC (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">40</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) demonstrated the synergistic effectiveness of this </span></p>
<p style="top:671.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">combination as an adjunct for headache in a subgroup of ani-</span></p>
<p style="top:682.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mals. NAC alone resulted in a significant behavioral recovery </span></p>
<p style="top:694.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">after injury not affected by the use of topiramate.</span></p>
<p style="top:324.0pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">DiScUSSiON</span></b></p>
<p style="top:346.5pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">main Findings</span></b></p>
<p style="top:360.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">To our knowledge, this systematic review is the first to summarize </span></p>
<p style="top:371.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and appraise the current evidence on the use of NAC in brain </span></p>
<p style="top:383.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">injury in human and in animal trials. The primary outcome of </span></p>
<p style="top:394.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">neurofunctional status, and the secondary outcomes of effect </span></p>
<p style="top:406.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">on markers of inflammation and oxidative stress at cellular and </span></p>
<p style="top:417.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tissue levels and safety, were assessed to a limited extend in the </span></p>
<p style="top:429.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">included studies. Overall, NAC improved the neurofunctional </span></p>
<p style="top:440.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">status in humans and animals, reduced levels of mediators of </span></p>
<p style="top:452.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">oxidative stress and the inflammatory response at tissue and cel-</span></p>
<p style="top:463.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">lular levels, cell death, and had no safety concerns. The effect of </span></p>
<p style="top:475.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">NAC at tissue and cellular levels reducing inflammation and the </span></p>
<p style="top:486.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">oxidative stress has a potential to decrease secondary brain injury, </span></p>
<p style="top:498.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">which can affect positively the neurofunctional outcomes in brain </span></p>
<p style="top:509.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">injury patients.</span></p>
<p style="top:521.0pt;left:317.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Under physiological conditions, endogenous antioxidant sys-</span></p>
<p style="top:532.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tems maintain the redox homeostasis within the mitochondria to </span></p>
<p style="top:544.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">avoid accumulation of cytotoxic free radicals or ROS, which are </span></p>
<p style="top:555.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">formed as result of regular cellular respiration and metabolism. </span></p>
<p style="top:567.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Brain injury causes dysregulation of this homeostatic process, </span></p>
<p style="top:578.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">with imbalance between ROS production and the cell&#x2019;s anti-</span></p>
<p style="top:590.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">oxidant capacity, resulting in exacerbation of oxidative processes </span></p>
<p style="top:601.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">71</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). The oxidative stress occurs within minutes of the primary </span></p>
<p style="top:613.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mechanical impact (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">72</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) and is an important contributor to the </span></p>
<p style="top:624.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">pathophysiology of acute brain injury. Excitotoxicity provokes </span></p>
<p style="top:636.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">an excessive calcium uptake, reduces the membrane potential of </span></p>
<p style="top:647.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mitochondria, increases production of ROS from the membrane </span></p>
<p style="top:659.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">enzyme complexes I and III, and subsequently reduces ATP </span></p>
<p style="top:670.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">production (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">18</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">73</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). ROS initiate tissue damage by contributing </span></p>
<p style="top:682.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">to metabolic failure, to the breakdown of macromolecules, and to </span></p>
<p style="top:693.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">the oxidization of proteins, lipids and nucleic acids. Additionally, </span></p>


<p style="top:707.2pt;left:155.7pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">taBle 5</span></b><span style="font-family:Arial,serif;font-size:7.0pt"> | Risk of bias in animal studies.</span></p>
<p style="top:707.2pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Reference</span></b></p>
<p style="top:630.8pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Random </span></b></p>
<p style="top:633.1pt;left:181.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">allocation</span></b></p>
<p style="top:586.7pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">allocation </span></b></p>
<p style="top:591.6pt;left:181.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">concealment</span></b></p>
<p style="top:539.5pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Blinding</span></b></p>
<p style="top:503.4pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">inclusion/</span></b></p>
<p style="top:502.9pt;left:181.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">exclusion </span></b></p>
<p style="top:498.8pt;left:191.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">criteria</span></b></p>
<p style="top:461.8pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Sample size </span></b></p>
<p style="top:460.0pt;left:181.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">calculation</span></b></p>
<p style="top:410.7pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">compliance </span></b></p>
<p style="top:409.8pt;left:181.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">with animal </span></b></p>
<p style="top:412.8pt;left:191.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">requirements</span></b></p>
<p style="top:356.0pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">conflicts </span></b></p>
<p style="top:359.8pt;left:181.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">of interests </span></b></p>
<p style="top:357.0pt;left:191.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">disclosed</span></b></p>
<p style="top:313.4pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Statistical </span></b></p>
<p style="top:307.2pt;left:181.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">model </span></b></p>
<p style="top:312.9pt;left:191.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">explained</span></b></p>
<p style="top:264.8pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">animals </span></b></p>
<p style="top:263.9pt;left:181.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">without </span></b></p>
<p style="top:271.4pt;left:191.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">comorbidity</span></b></p>
<p style="top:218.4pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">test </span></b></p>
<p style="top:222.6pt;left:181.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">animal </span></b></p>
<p style="top:222.6pt;left:191.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">details</span></b></p>
<p style="top:183.2pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">every </span></b></p>
<p style="top:185.0pt;left:181.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">animal </span></b></p>
<p style="top:191.6pt;left:191.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">accounted</span></b></p>
<p style="top:142.0pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Dose-</span></b></p>
<p style="top:147.4pt;left:181.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">response </span></b></p>
<p style="top:142.3pt;left:191.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">model</span></b></p>
<p style="top:107.7pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">Optimal </span></b></p>
<p style="top:101.9pt;left:181.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">time </span></b></p>
<p style="top:107.6pt;left:191.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">window </span></b></p>
<p style="top:102.7pt;left:200.8pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">used</span></b></p>
<p style="top:73.2pt;left:172.3pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt">total</span></b></p>
<p style="top:707.1pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Abdel-Baki et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">37</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:621.2pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:574.4pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.1pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.0pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:346.3pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:302.1pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.7pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:178.4pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:137.3pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:217.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">7/13</span></p>
<p style="top:707.1pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Chen et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">38</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:622.1pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:574.4pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.0pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:345.4pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:302.1pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.7pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:179.3pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.3pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:227.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">8/13</span></p>
<p style="top:707.1pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Du et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">39</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:622.1pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:574.4pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:492.4pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:446.2pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.0pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:346.3pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:302.1pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.7pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:179.3pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:136.4pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:100.0pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:236.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">9/13</span></p>
<p style="top:707.1pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Eakin et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">40</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:622.1pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:574.4pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.0pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:346.3pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:302.1pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.7pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:179.3pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.3pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:246.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">9/13</span></p>
<p style="top:707.2pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Ellis et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">41</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:621.2pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:574.4pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.0pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:345.4pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:302.1pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:255.8pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:216.0pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:179.3pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.3pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:255.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">5/13</span></p>
<p style="top:707.2pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Ewert et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">42</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:622.1pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:574.4pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:346.3pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:302.1pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:179.3pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.3pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:265.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">9/13</span></p>
<p style="top:707.2pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Gunther et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">43</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:622.1pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:574.4pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:346.3pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:302.1pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:179.3pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.3pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">9/13</span></p>
<p style="top:707.2pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Haber et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">44</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:621.2pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:574.4pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:345.4pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:302.1pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:178.4pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:137.3pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:284.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">6/13</span></p>
<p style="top:707.2pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Hicdonmez et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">45</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:622.1pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:574.4pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:345.4pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:302.1pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:179.3pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.3pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:293.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">8/13</span></p>
<p style="top:707.2pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Kawoos et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">46</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:621.2pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:574.4pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:346.3pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:302.1pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:179.3pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.3pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:99.1pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:72.2pt;left:303.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">7/13</span></p>
<p style="top:707.2pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Naziroglu et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">47</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:622.1pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:574.4pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:346.3pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:302.1pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:179.3pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.3pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:312.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">9/13</span></p>
<p style="top:707.2pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Pandya et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">48</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:622.1pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:575.3pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:531.2pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:491.5pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:346.3pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:302.1pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:178.4pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:137.3pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:74.2pt;left:322.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">10/13</span></p>
<p style="top:707.2pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Senol et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">20</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:622.1pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:574.4pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:346.4pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:302.2pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.0pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:179.3pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.3pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:331.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">8/13</span></p>
<p style="top:707.2pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Silva et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">49</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:621.2pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:574.4pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:345.5pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:301.3pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:255.9pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:216.0pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:178.4pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:137.3pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:99.1pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:72.2pt;left:341.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">2/13</span></p>
<p style="top:707.2pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Thomale et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">50</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:621.2pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:574.4pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:346.4pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:302.2pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:179.3pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.3pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:350.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">8/13</span></p>
<p style="top:707.2pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Thomale et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">51</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:622.1pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:574.4pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:346.4pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:302.2pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:179.3pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.4pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:360.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">9/13</span></p>
<p style="top:707.2pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Xiong et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">52</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:621.2pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:574.4pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:345.5pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:302.2pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:178.4pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:137.4pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:369.9pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">6/13</span></p>
<p style="top:707.2pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Xiong et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">53</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:621.2pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:574.4pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:345.5pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:302.2pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:178.4pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:137.4pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:379.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">6/13</span></p>
<p style="top:707.2pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yi and Hazell (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">54</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:621.2pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:574.4pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:345.5pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:302.2pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:179.3pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.3pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:388.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">7/13</span></p>
<p style="top:707.2pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yi et&#xa0;al. (</span><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">55</span><span style="font-family:Arial,serif;font-size:7.0pt">)</span></p>
<p style="top:621.2pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:574.4pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:530.3pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:491.5pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:446.2pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:396.1pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:345.5pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">No</span></p>
<p style="top:302.2pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:256.8pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:216.9pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:179.3pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:137.3pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:100.0pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">Yes</span></p>
<p style="top:72.2pt;left:398.3pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">7/13</span></p>
<p style="top:625.8pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">10/20</span></p>
<p style="top:577.0pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1/20</span></p>
<p style="top:532.9pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1/20</span></p>
<p style="top:494.1pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">1/20</span></p>
<p style="top:448.8pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">0/20</span></p>
<p style="top:399.7pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">20/20</span></p>
<p style="top:350.0pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">11/20</span></p>
<p style="top:305.8pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">20/20</span></p>
<p style="top:260.4pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">18/20</span></p>
<p style="top:220.5pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">15/20</span></p>
<p style="top:182.9pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">14/20</span></p>
<p style="top:141.0pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">19/20</span></p>
<p style="top:103.6pt;left:407.8pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt">18/20</span></p>
<p style="top:741.9pt;left:292.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">10</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>


<p style="top:741.9pt;left:292.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">11</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>
<p style="top:61.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ROS enhance other secondary injury processes, including the </span></p>
<p style="top:72.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">excitotoxicity itself, inflammation, hyperadrenergic activation </span></p>
<p style="top:84.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">13</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), mitochondrial dysfunction, which ultimately will lead to </span></p>
<p style="top:95.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">irreversible cell damage and death (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">72</span><span style="font-family:MinionPro,serif;font-size:9.5pt">).</span></p>
<p style="top:107.4pt;left:56.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The recent interest in therapies targeting the damaged brain </span></p>
<p style="top:118.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tissue, such as NAC, NACA, and the use of beta-blockers (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">74</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) </span></p>
<p style="top:130.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">are due to a better understanding of the pathophysiology of brain </span></p>
<p style="top:141.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">damage at tissue, cellular and molecular levels. Studies in animals </span></p>
<p style="top:153.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and humans are focusing on identifying biomarkers of tissue </span></p>
<p style="top:164.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">damage, impaired metabolism, inflammation, oxidative stress, </span></p>
<p style="top:176.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and cell death. Several biomarkers are currently associated with </span></p>
<p style="top:187.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">outcome in TBI and have been used as prognostic indicators. As </span></p>
<p style="top:199.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">an example, the hyperadrenergic response and catecholamine </span></p>
<p style="top:211.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">surge occurring in the early post-injury period following TBI </span></p>
<p style="top:222.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">was independently associated with unfavorable outcome and </span></p>
<p style="top:234.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">peripheral inflammatory cytokine/chemokine dysregulation in </span></p>
<p style="top:245.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">patients with moderate to severe isolated TBI (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">13</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">16</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Similarly, </span></p>
<p style="top:257.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">studies investigating the safety and efficacy of beta blockers in </span></p>
<p style="top:268.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">patients with acute TBI are currently ongoing (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">74</span><span style="font-family:MinionPro,serif;font-size:9.5pt">).</span></p>
<p style="top:280.0pt;left:56.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Despite considerable investment by both the pharmaceuti-</span></p>
<p style="top:291.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cal industry and the US National Institutes of Health, to date, </span></p>
<p style="top:303.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">there are no pharmacotherapies that will definitively improve </span></p>
<p style="top:314.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">unfavorable outcomes post-brain injury. Human literature </span></p>
<p style="top:326.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">lacks properly designed phase 2 and 3 clinical studies evaluat-</span></p>
<p style="top:337.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ing new drugs, including NAC and NACA, as demonstrated in </span></p>
<p style="top:349.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">this review. There is a lack of studies that properly assess the </span></p>
<p style="top:360.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">effects of these promising compounds on the neurofunctional </span></p>
<p style="top:372.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">outcome, including cognition. Only one RCT (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">35</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) with an </span></p>
<p style="top:383.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">adequately powered sample size calculation was obtained. This </span></p>
<p style="top:395.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">study reported beneficial effects of NAC on patients with mild </span></p>
<p style="top:406.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">TBI-related balance disturbances and headache only. Conversely, </span></p>
<p style="top:418.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">a larger number of pre-clinical studies employing standardized </span></p>
<p style="top:429.5pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">brain injury animal models reported more convincing evidence </span></p>
<p style="top:441.0pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of the utility of NAC/NACA. These models, previously validated </span></p>
<p style="top:452.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in the animal literature (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">75</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) have demonstrated improvements </span></p>
<p style="top:464.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in behavioral tasks related to memory, cognition, and auditory </span></p>
<p style="top:475.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">complications. Moreover, assessment of biomarkers of oxidative </span></p>
<p style="top:487.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">stress, inflammation (pro-/anti-inflammatory cytokines), and </span></p>
<p style="top:498.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cell death (apoptosis-related proteins) was conducted mostly in </span></p>
<p style="top:510.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">the animal studies. They have demonstrated substantial modula-</span></p>
<p style="top:521.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tion and downregulation of these pathways after the application </span></p>
<p style="top:533.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of NAC. Evidence on other outcomes, such as the effect of NAC </span></p>
<p style="top:544.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">on brain perfusion, ICP, size of contusion, and brain reactivity </span></p>
<p style="top:556.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">remains modest to date.</span></p>
<p style="top:576.9pt;left:45.4pt;line-height:12.0pt"><b><i><span style="font-family:Arial,serif;font-size:12.0pt">N-</span></i></b><b><span style="font-family:Arial,serif;font-size:12.0pt">acetylcysteine amide</span></b></p>
<p style="top:590.4pt;left:45.4pt;line-height:9.5pt"><i><span style="font-family:MinionPro,serif;font-size:9.5pt">N-</span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">acetylcysteine amide is related to NAC with exception of a </span></p>
<p style="top:601.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">minor change in the chemical structure, an amide side chain </span></p>
<p style="top:613.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">substitution, that gives the compound a neutral charge and </span></p>
<p style="top:624.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">improves hydrophobicity and lipophilicity (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">76</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). As result of this </span></p>
<p style="top:636.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">minor modification, the efficacy of NACA as compared to NAC </span></p>
<p style="top:647.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">is significantly enhanced. The new physiochemical and pharma-</span></p>
<p style="top:659.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cological properties lead to an easier penetration into the BBB, </span></p>
<p style="top:670.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mitochondria, and other cellular constituents. NACA seems to </span></p>
<p style="top:682.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">be a more attractive drug, with possibly stronger therapeutic </span></p>
<p style="top:693.9pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">properties for modulation of inflammation and oxidative stress </span></p>
<p style="top:705.4pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">post TBI due to its superior BBB permeability. It could be even </span></p>
<p style="top:61.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">more protective in TBI by simultaneously and effectively reduc-</span></p>
<p style="top:73.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ing the concomitant trauma-induced systemic inflammatory </span></p>
<p style="top:84.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">processes by reducing pulmonary injury (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">46</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). For example, in a </span></p>
<p style="top:96.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">study (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">77</span><span style="font-family:MinionPro,serif;font-size:9.5pt">) where rats were administered with NACA and were </span></p>
<p style="top:107.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">exposed to a blast injury, there was a significant reduction of the </span></p>
<p style="top:119.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">infiltration of neutrophils into the lung and immunomodula-</span></p>
<p style="top:130.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tion. NACA facilitated lung recovery from the inflammatory </span></p>
<p style="top:142.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">damage, which can be important in cases of severe ALI/ARDS </span></p>
<p style="top:153.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and development of systemic inflammation that could further </span></p>
<p style="top:165.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">damage affect the already injured brain. Limited research on </span></p>
<p style="top:176.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">NACA has demonstrated that significant levels are detect-</span></p>
<p style="top:188.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">able in the brain after oral and intraperitoneal administration, </span></p>
<p style="top:199.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">compared to NAC (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">21</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). If NACA is formulated as a co-crystal </span></p>
<p style="top:211.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">with an excipient, it may have a prolonged plasmatic half-life </span></p>
<p style="top:222.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">compared to NAC (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">78</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). Oxidative stress measures were reported </span></p>
<p style="top:234.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in a model of intracellular oxidation in human red blood cells </span></p>
<p style="top:245.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">79</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). In this experiment, NACA reduced oxidative activity five </span></p>
<p style="top:257.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">times more effectively than NAC and restored 91% of endog-</span></p>
<p style="top:268.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">enous GSH compared to 15% with NAC, which may suggest </span></p>
<p style="top:280.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">an easier penetration of NACA through cellular membranes. </span></p>
<p style="top:291.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The rationale for use of NACA in brain injury therefore seems </span></p>
<p style="top:303.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">robust. However, additional pre-clinical and clinical evidence is </span></p>
<p style="top:314.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">still required to better establish both mechanism of action and </span></p>
<p style="top:326.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">therapeutic efficacy.</span></p>
<p style="top:346.9pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Strengths and weaknesses of this Review</span></b></p>
<p style="top:360.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">To our knowledge, no systematic review has been conducted </span></p>
<p style="top:371.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in human and animal studies addressing the effects of NAC </span></p>
<p style="top:383.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and NACA on neurofunctional outcome, tissue biomarkers of </span></p>
<p style="top:394.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">inflammation and oxidative stress, and safety in brain injury. </span></p>
<p style="top:406.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Major limitations of this review are related to the weaknesses of </span></p>
<p style="top:417.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">many of the studies included. For example, it was not feasible </span></p>
<p style="top:429.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">to conduct a meta-analysis due to clinical and methodological </span></p>
<p style="top:440.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">heterogeneity across the studies, which subsequently precluded </span></p>
<p style="top:452.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">analysis of potential publications bias. Furthermore, in review-</span></p>
<p style="top:463.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ing current evidence, the main limiting factor observed was that </span></p>
<p style="top:475.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">pre-clinical research on NAC and NACA in TBI is substantially </span></p>
<p style="top:486.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">more robust compared to clinical research. We identified several </span></p>
<p style="top:498.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">studies conducted in animals and only a few in humans. Pre-</span></p>
<p style="top:510.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">clinical work was mostly performed using previously validated </span></p>
<p style="top:521.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">animal models of brain injury; however, regimens of NAC and </span></p>
<p style="top:533.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">NACA administration, including dose (single vs. multiple), </span></p>
<p style="top:544.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">route (oral vs. intravenous), and time post injury still warrant </span></p>
<p style="top:556.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">better standardization. In addition, the effect of both drugs on </span></p>
<p style="top:567.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">other important biomarkers of brain and BBB damage predic-</span></p>
<p style="top:579.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tors of outcome in TBI, such as the protein S100 beta (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">80</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">81</span><span style="font-family:MinionPro,serif;font-size:9.5pt">), </span></p>
<p style="top:590.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">need to be evaluated in pre-clinical and clinical studies. The </span></p>
<p style="top:602.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">use of NAC or NACA concomitantly with other drugs, such as </span></p>
<p style="top:613.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">the ones cited in this review, need more robust investigation </span></p>
<p style="top:625.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">to confirm whether synergistic or complimentary effects may </span></p>
<p style="top:636.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">occur. Moreover, the human literature presented in this review </span></p>
<p style="top:648.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">is restricted to small RCTs, not adequately powered to detect </span></p>
<p style="top:659.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">clinical differences, such as favorable or unfavorable neurofunc-</span></p>
<p style="top:671.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tional outcome, mortality, and drug safety. Studies in humans </span></p>
<p style="top:682.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">also may lack generalizability, as they were conducted only in </span></p>
<p style="top:694.0pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">military personnel with specific blast injuries and in cases of </span></p>
<p style="top:705.5pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">pediatric neurotrauma.</span></p>


<p style="top:741.9pt;left:292.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">12</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>
<p style="top:61.1pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Unanswered Questions and Future </span></b></p>
<p style="top:75.1pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Research</span></b></p>
<p style="top:88.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Although studies conducted in animal models of brain injury </span></p>
<p style="top:100.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">can provide insight and guidance to NAC and NACA use in </span></p>
<p style="top:111.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">TBI in patients, assessment and management of patients with </span></p>
<p style="top:123.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">TBI during clinical practice is considerably different from </span></p>
<p style="top:134.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">addressing TBI in these established animal models of brain </span></p>
<p style="top:146.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">injury (</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#6c6e70">82</span><span style="font-family:MinionPro,serif;font-size:9.5pt">). These differences may challenge the subsequent </span></p>
<p style="top:157.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">long-term outcome evaluation of NAC/NACA effects on TBI. </span></p>
<p style="top:169.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Ultimately, findings from animal models must be translated </span></p>
<p style="top:180.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and validated in the clinical setting, and this is importantly </span></p>
<p style="top:192.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">demonstrated in this review. Such knowledge translation </span></p>
<p style="top:203.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">strategies require major efforts and collaboration between </span></p>
<p style="top:215.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">clinicians and scientists, and can be challenging to achieve. </span></p>
<p style="top:226.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">However, those efforts are justified considering that TBI is a </span></p>
<p style="top:238.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">global leading cause of death and disability, have a substantial </span></p>
<p style="top:249.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">economic burden due the expenses in immediate and late care, </span></p>
<p style="top:261.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and affects individuals regardless of age, sex, or race worldwide. </span></p>
<p style="top:272.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Phase 3 and 4 trials are warranted for a better understanding </span></p>
<p style="top:284.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of the efficacy and safety of NAC and NACA in TBI patients. </span></p>
<p style="top:295.6pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Some questions still need to be answered in phase 1 and 2 tri-</span></p>
<p style="top:307.1pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">als. However, we believe that with the previous knowledge of </span></p>
<p style="top:318.7pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">efficacy and safety of NAC use in other clinical settings, a RCT </span></p>
<p style="top:330.2pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">is warranted. Futures studies should include a double-blind, </span></p>
<p style="top:341.7pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">placebo controlled, parallel trial, adequately powered to detect </span></p>
<p style="top:353.2pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">differences in laboratory and, more importantly, meaningful </span></p>
<p style="top:364.7pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">clinical endpoints, including neurofunctional outcome, mor-</span></p>
<p style="top:376.2pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tality, and adverse events. We hope that this review will enable </span></p>
<p style="top:387.7pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">clinicians to better appreciate the current state of NAC/NACA </span></p>
<p style="top:399.2pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">use in TBI and prompt investigators to conduct well designed </span></p>
<p style="top:410.7pt;left:45.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">studies in future.</span></p>
<p style="top:61.1pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">cONclUSiON</span></b></p>
<p style="top:83.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">In summary, our systematic review demonstrated moderate qual-</span></p>
<p style="top:94.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ity evidence of efficacy and safety of the use of NAC and NACA </span></p>
<p style="top:106.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in pre-clinical studies. However, these studies still have important </span></p>
<p style="top:117.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">questions to be addressed and are substantially heterogeneous, </span></p>
<p style="top:129.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">which precludes a more robust interpretation. We found very </span></p>
<p style="top:140.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">limited clinical research addressing this subject in brain injury </span></p>
<p style="top:152.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">patients. Overall, the literature reported improvement of some </span></p>
<p style="top:163.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">aspects of neurofunctional outcome in human and animals, </span></p>
<p style="top:175.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">with decreased oxidative stress and inflammation at cellular and </span></p>
<p style="top:186.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">molecular levels, and no safety concerns. The promising effects </span></p>
<p style="top:198.1pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of these drugs on the outcome of TBI warrant further animal </span></p>
<p style="top:209.6pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">research and translation to the clinical setting.</span></p>
<p style="top:236.2pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">aUtHOR cONtRiBUtiONS</span></b></p>
<p style="top:258.2pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">LL was the method expert responsible for study design, planning </span></p>
<p style="top:269.7pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of data collection, data analysis, draft, and revision of the manu-</span></p>
<p style="top:281.3pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">script. JB and UA participated in the study design, data collection </span></p>
<p style="top:292.8pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and analysis, and drafting of the manuscript. BN and SR were the </span></p>
<p style="top:304.3pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">content experts and participated in the study design, data analysis </span></p>
<p style="top:315.8pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and revision of the manuscript. HT and AN participated in data </span></p>
<p style="top:327.3pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">analysis and revision of the manuscript. The final manuscript was </span></p>
<p style="top:338.8pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">approved by all authors.</span></p>
<p style="top:365.4pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">SUPPlemeNtaRy mateRial</span></b></p>
<p style="top:387.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The Supplementary Material for this article can be found online </span></p>
<p style="top:398.9pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">at http://www.frontiersin.org/articles/10.3389/fneur.2017.00744/</span></p>
<p style="top:410.4pt;left:306.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">full#supplementary-material.</span></p>
<p style="top:447.9pt;left:45.4pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">ReFeReNceS</span></b></p>
<p style="top:469.5pt;left:48.9pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">1. Centers for Disease Control and Prevention. Nonfatal traumatic brain injuries </span></p>
<p style="top:479.0pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">related to sports and recreation activities among persons aged </span><span style="font-family:STIXGeneral,serif;font-size:7.5pt">&lt;=</span><span style="font-family:MinionPro,serif;font-size:7.5pt">19 years &#x2013;  </span></p>
<p style="top:488.5pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">United States, 2001&#x2013;2009. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">MMWR Morb Mortal Wkly Rep</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2011) 60 </span></p>
<p style="top:498.0pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">(39):1337&#x2013;42. </span></p>
<p style="top:507.5pt;left:48.9pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">2. Hyder AA, Wunderlich CA, Puvanachandra P, Gururaj G, Kobusingye OC. The </span></p>
<p style="top:517.0pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">impact of traumatic brain injuries: a global perspective. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">NeuroRehabilitation</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> </span></p>
<p style="top:526.5pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">(2007) 22(5):341&#x2013;53. </span></p>
<p style="top:536.0pt;left:48.9pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">3. Faul M, Xu L, Wald MM, Coronado VG. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Traumatic Brain Injury in the United </span></i></p>
<p style="top:545.5pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">States: Emergency Department Visits, Hospitalizations and Deaths 2002&#x2013;2006</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">. </span></p>
<p style="top:555.0pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">Atlanta, GA: Centers for Disease Control and Prevention, National Center for </span></p>
<p style="top:564.5pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">Injury Prevention and Control (2010).</span></p>
<p style="top:574.0pt;left:48.9pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">4. Thurman DJ, Alverson C, Dunn KA, Guerrero J, Sniezek JE. Traumatic brain </span></p>
<p style="top:583.5pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">injury in the United States: a public health perspective. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Head Trauma Rehabil</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> </span></p>
<p style="top:593.0pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">(1999) 14(6):602&#x2013;15. doi:10.1097/00001199-199912000-00009 </span></p>
<p style="top:602.5pt;left:48.9pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">5. Woo BH, Nesathurai S. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">The Rehabilitation of Patients with Traumatic Brain </span></i></p>
<p style="top:612.0pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Injury</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">. Malden, MA: Blackwell Science (2005).</span></p>
<p style="top:621.5pt;left:48.9pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">6. McAllister TW. Neurobehavioral sequelae of traumatic brain injury: evalu-</span></p>
<p style="top:631.0pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">ation and management. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">World Psychiatry</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2008) 7(1):3&#x2013;10. doi:10.1002/j. </span></p>
<p style="top:640.5pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">2051-5545.2008.tb00139.x </span></p>
<p style="top:650.0pt;left:48.9pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">7. Davis AE. Mechanisms of traumatic brain injury: biomechanical, struc-</span></p>
<p style="top:659.5pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">tural and cellular considerations. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Crit Care Nurs Q</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2000) 23(3):1&#x2013;13. </span></p>
<p style="top:669.0pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1097/00002727-200011000-00002 </span></p>
<p style="top:678.5pt;left:48.7pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">8. Ziebell JM, Morganti-Kossmann MC. Involvement of pro- and anti-in-</span></p>
<p style="top:688.0pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">flammatory cytokines and chemokines in the pathophysiology of trau-</span></p>
<p style="top:697.5pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">matic brain injury. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Neurotherapeutics</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2010) 7(1):22&#x2013;30. doi:10.1016/j.</span></p>
<p style="top:707.0pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">nurt.2009.10.016 </span></p>
<p style="top:450.5pt;left:309.7pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">9. Gaetz M. The neurophysiology of brain injury. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Clin Neurophysiol</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2004) </span></p>
<p style="top:460.0pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">115(1):4&#x2013;18. doi:10.1016/S1388-2457(03)00258-X </span></p>
<p style="top:469.5pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">10. Prins M, Greco T, Alexander D, Giza CC. The pathophysiology of traumatic </span></p>
<p style="top:479.0pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">brain injury at a glance. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Dis Model Mech</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2013) 6(6):1307&#x2013;15. doi:10.1242/</span></p>
<p style="top:488.5pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">dmm.011585 </span></p>
<p style="top:498.0pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">11. Hiebert JB, Shen Q, Thimmesch AR, Pierce JD. Traumatic brain injury and </span></p>
<p style="top:507.5pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">mitochondrial dysfunction. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Am J Med Sci</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2015) 350(2):132&#x2013;8. doi:10.1097/</span></p>
<p style="top:517.0pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">MAJ.0000000000000506 </span></p>
<p style="top:526.5pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">12. Corps KN, Roth TL, McGavern DB. Inflammation and neuroprotection in </span></p>
<p style="top:536.0pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">traumatic brain injury. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">JAMA Neurol</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2015) 72(3):355&#x2013;62. doi:10.1001/</span></p>
<p style="top:545.5pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">jamaneurol.2014.3558 </span></p>
<p style="top:555.0pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">13. Rizoli SB, Jaja BN, Di Battista AP, Rhind SG, Neto AC, da Costa L, et&#xa0;al. </span></p>
<p style="top:564.5pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">Catecholamines as outcome markers in isolated traumatic brain injury: the </span></p>
<p style="top:574.0pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">COMA-TBI study. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Crit Care</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2017) 21(1):37. doi:10.1186/s13054-017-1620-6 </span></p>
<p style="top:583.6pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">14. Bramlett HM, Dietrich WD. Progressive damage after brain and spinal cord </span></p>
<p style="top:593.1pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">injury: pathomechanisms and treatment strategies. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Prog Brain Res</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2007) </span></p>
<p style="top:602.6pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">161:125&#x2013;41. doi:10.1016/S0079-6123(06)61009-1 </span></p>
<p style="top:612.1pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">15. Bell JD, Rhind SG, Di Battista AP, Macdonald RL, Baker AJ. Biomarkers of gly-</span></p>
<p style="top:621.6pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">cocalyx injury are associated with delayed cerebral ischemia following aneu-</span></p>
<p style="top:631.1pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">rysmal subarachnoid hemorrhage: a case series supporting a new hypothesis. </span></p>
<p style="top:640.6pt;left:320.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Neurocrit Care</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2017) 26(3):339&#x2013;47. doi:10.1007/s12028-016-0357-4 </span></p>
<p style="top:650.1pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">16. Di Battista AP, Rhind SG, Hutchison MG, Hassan S, Shiu MY, Inaba K, </span></p>
<p style="top:659.6pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">et&#xa0; al. Inflammatory cytokine and chemokine profiles are associated with </span></p>
<p style="top:669.1pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">patient outcome and the hyperadrenergic state following acute brain injury. </span></p>
<p style="top:678.6pt;left:320.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Neuroinflammation</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2016) 13:40. doi:10.1186/s12974-016-0500-3 </span></p>
<p style="top:688.1pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">17. Marklund N, Bakshi A, Castelbuono DJ, Conte V, McIntosh TK. Evaluation of </span></p>
<p style="top:697.6pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">pharmacological treatment strategies in traumatic brain injury. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Curr Pharm </span></i></p>
<p style="top:707.1pt;left:320.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Des</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2006) 12(13):1645&#x2013;80. doi:10.2174/138161206776843340 </span></p>


<p style="top:741.9pt;left:292.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">13</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>
<p style="top:61.5pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">18. Hagberg H, Mallard C, Rousset CI, Thornton C. Mitochondria: hub of </span></p>
<p style="top:71.0pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">injury responses in the developing brain. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Lancet Neurol</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2014) 13(2):217&#x2013;32. </span></p>
<p style="top:80.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1016/S1474-4422(13)70261-8 </span></p>
<p style="top:90.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">19. Shen Q, Hiebert JB, Hartwell J, Thimmesch AR, Pierce JD. Systematic review </span></p>
<p style="top:99.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">of traumatic brain injury and the impact of antioxidant therapy on clinical </span></p>
<p style="top:109.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">outcomes. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Worldviews Evid Based Nurs</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2016) 13(5):380&#x2013;9. doi:10.1111/</span></p>
<p style="top:118.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">wvn.12167 </span></p>
<p style="top:128.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">20. Senol N, Naziroglu M, Yuruker V. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine and selenium modulate </span></p>
<p style="top:137.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">oxidative stress, antioxidant vitamin and cytokine values in traumatic brain </span></p>
<p style="top:147.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">injury-induced rats. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Neurochem Res</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2014) 39(4):685&#x2013;92. doi:10.1007/</span></p>
<p style="top:156.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">s11064-014-1255-9 </span></p>
<p style="top:166.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">21. Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological </span></p>
<p style="top:175.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">activities of </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Biochim Biophys Acta</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2013) 1830(8):4117&#x2013;29. </span></p>
<p style="top:185.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1016/j.bbagen.2013.04.016 </span></p>
<p style="top:194.6pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">22. Deepmala D, Slattery J, Kumar N, Delhey L, Berk M, Dean O, et&#xa0;al. Clinical trials </span></p>
<p style="top:204.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">of </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine in psychiatry and neurology: a systematic review. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Neurosci </span></i></p>
<p style="top:213.6pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Biobehav Rev</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2015) 55:294&#x2013;321. doi:10.1016/j.neubiorev.2015.04.015 </span></p>
<p style="top:223.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">23. Millea PJ. N-acetylcysteine: multiple clinical applications. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Am Fam Physician</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> </span></p>
<p style="top:232.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">(2009) 80(3):265&#x2013;9. </span></p>
<p style="top:242.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">24. Nikoo M, Radnia H, Farokhnia M, Mohammadi MR, Akhondzadeh S. </span></p>
<p style="top:251.6pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine as an adjunctive therapy to risperidone for treatment </span></p>
<p style="top:261.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">of irritability in autism: a randomized, double-blind, placebo-controlled </span></p>
<p style="top:270.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">clinical trial of efficacy and safety. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Clin Neuropharmacol</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2015) 38(1):11&#x2013;7. </span></p>
<p style="top:280.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1097/WNF.0000000000000063 </span></p>
<p style="top:289.6pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">25. Dean O, Giorlando F, Berk M. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine in psychiatry: current ther-</span></p>
<p style="top:299.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">apeutic evidence and potential mechanisms of action. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Psychiatry Neurosci</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> </span></p>
<p style="top:308.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">(2011) 36(2):78&#x2013;86. doi:10.1503/jpn.100057 </span></p>
<p style="top:318.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">26. Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, et&#xa0;al. </span></p>
<p style="top:327.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">The efficacy of adjunctive </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine in major depressive disorder: a </span></p>
<p style="top:337.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">double-blind, randomized, placebo-controlled trial. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Clin Psychiatry</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2014) </span></p>
<p style="top:346.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">75(6):628&#x2013;36. doi:10.4088/JCP.13m08454 </span></p>
<p style="top:356.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">27. Wiest DB, Chang E, Fanning D, Garner S, Cox T, Jenkins DD. Antenatal phar-</span></p>
<p style="top:365.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">macokinetics and placental transfer of N-acetylcysteine in chorioamnionitis </span></p>
<p style="top:375.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">for fetal neuroprotection. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Pediatr</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2014) 165(4):672&#x2013;7.e672. doi:10.1016/j.</span></p>
<p style="top:384.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">jpeds.2014.06.044 </span></p>
<p style="top:394.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">28. Levin SW, Baker EH, Zein WM, Zhang Z, Quezado ZM, Miao N, et&#xa0;al. Oral </span></p>
<p style="top:403.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">cysteamine bitartrate and </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine for patients with infantile neuro-</span></p>
<p style="top:413.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">nal ceroid lipofuscinosis: a pilot study. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Lancet Neurol</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2014) 13(8):777&#x2013;87. </span></p>
<p style="top:422.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1016/S1474-4422(14)70142-5 </span></p>
<p style="top:432.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">29. Mahmoud KM, Ammar AS. Effect of </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine on cardiac injury </span></p>
<p style="top:441.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">and oxidative stress after abdominal aortic aneurysm repair: a random-</span></p>
<p style="top:451.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">ized controlled trial. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Acta Anaesthesiol Scand</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2011) 55(8):1015&#x2013;21. </span></p>
<p style="top:460.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1111/j.1399-6576.2011.02492.x </span></p>
<p style="top:470.2pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">30. Ozaydin M, Icli A, Yucel H, Akcay S, Peker O, Erdogan D, et&#xa0;al. Metoprolol </span></p>
<p style="top:479.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial </span></p>
<p style="top:489.2pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">fibrillation: a randomized, double-blind, placebo-controlled study. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Eur Heart </span></i></p>
<p style="top:498.7pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2013) 34(8):597&#x2013;604. doi:10.1093/eurheartj/ehs423 </span></p>
<p style="top:508.2pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">31. Atlas D, Melamed E, Offen D. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Brain Targeted Low Molecular Weight Hydrophobic </span></i></p>
<p style="top:517.7pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Antioxidant Compounds</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">. United States patent US 5874468 (1999).</span></p>
<p style="top:527.2pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">32. Sunitha K, Hemshekhar M, Thushara RM, Santhosh MS, Yariswamy M, </span></p>
<p style="top:536.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">Kemparaju K, et&#xa0;al. N-acetylcysteine amide: a derivative to fulfill the promises </span></p>
<p style="top:546.2pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">of </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Free Radic Res</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2013) 47(5):357&#x2013;67. doi:10.3109/107157</span></p>
<p style="top:555.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">62.2013.781595 </span></p>
<p style="top:565.2pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">33. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et&#xa0;al. </span></p>
<p style="top:574.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">The PRISMA statement for reporting systematic reviews and meta-analyses of </span></p>
<p style="top:584.2pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">studies that evaluate health care interventions: explanation and elaboration. </span></p>
<p style="top:593.7pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">PLoS Med</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2009) 6(7):e1000100. doi:10.1371/journal.pmed.1000100 </span></p>
<p style="top:603.2pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">34. Amen DG, Wu JC, Taylor D, Willeumier K. Reversing brain damage in former </span></p>
<p style="top:612.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">NFL players: implications for traumatic brain injury and substance abuse </span></p>
<p style="top:622.2pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">rehabilitation. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Psychoactive Drugs</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2011) 43(1):1&#x2013;5. doi:10.1080/02791072</span></p>
<p style="top:631.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">.2011.566489 </span></p>
<p style="top:641.2pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">35. Hoffer ME, Balaban C, Slade MD, Tsao JW, Hoffer B. Amelioration of acute </span></p>
<p style="top:650.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">sequelae of blast induced mild traumatic brain injury by N-acetyl cysteine: </span></p>
<p style="top:660.2pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">a double-blind, placebo controlled study. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">PLoS One</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2013) 8(1):e54163. </span></p>
<p style="top:669.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1371/journal.pone.0054163 </span></p>
<p style="top:679.2pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">36. Clark RSB, Empey PE, Bayir H, Rosario BL, Poloyac SM, Kochanek PM, et&#xa0;al. </span></p>
<p style="top:688.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">Phase I randomized clinical trial of N-acetylcysteine in combination with an </span></p>
<p style="top:698.2pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">adjuvant probenecid for treatment of severe traumatic brain injury in children. </span></p>
<p style="top:707.7pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">PLoS One</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2017) 12(7):e0180280. doi:10.1371/journal.pone.0180280 </span></p>
<p style="top:61.7pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">37. Abdel Baki SG, Schwab B, Haber M, Fenton AA, Bergold PJ. Minocycline syn-</span></p>
<p style="top:71.2pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">ergizes with N-acetylcysteine and improves cognition and memory following </span></p>
<p style="top:80.7pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">traumatic brain injury in rats. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">PLoS One</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2010) 5(8):e12490. doi:10.1371/</span></p>
<p style="top:90.2pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">journal.pone.0012490 </span></p>
<p style="top:99.7pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">38. Chen G, Shi J, Hu Z, Hang C. Inhibitory effect on cerebral inflammatory </span></p>
<p style="top:109.2pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">response following traumatic brain injury in rats: a potential neuroprotective </span></p>
<p style="top:118.7pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">mechanism of N-acetylcysteine. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Mediators Inflamm</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2008) 2008:716458. </span></p>
<p style="top:128.2pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1155/2008/716458 </span></p>
<p style="top:137.7pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">39. Du X, Ewert DL, Cheng W, West MB, Lu J, Li W, et&#xa0;al. Effects of antioxidant </span></p>
<p style="top:147.2pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">treatment on blast-induced brain injury. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">PLoS One</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2013) 8(11):e80138. </span></p>
<p style="top:156.7pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1371/journal.pone.0080138 </span></p>
<p style="top:166.2pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">40. Eakin K, Baratz-Goldstein R, Pick CG, Zindel O, Balaban CD, Hoffer ME, </span></p>
<p style="top:175.7pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">et&#xa0;al. Efficacy of </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetyl cysteine in traumatic brain injury. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">PLoS One</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2014) </span></p>
<p style="top:185.3pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">9(4):e90617. doi:10.1371/journal.pone.0090617 </span></p>
<p style="top:194.8pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">41. Ellis EF, Dodson LY, Police RJ. Restoration of cerebrovascular responsiveness </span></p>
<p style="top:204.3pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">to hyperventilation by the oxygen radical scavenger </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine follow-</span></p>
<p style="top:213.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">ing experimental traumatic brain injury. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Neurosurg</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (1991) 75(5):774&#x2013;9. </span></p>
<p style="top:223.3pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.3171/jns.1991.75.5.0774 </span></p>
<p style="top:232.8pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">42. Ewert DL, Lu J, Li W, Du X, Floyd R, Kopke R. Antioxidant treatment </span></p>
<p style="top:242.3pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">reduces blast-induced cochlear damage and hearing loss. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Hear Res</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2012) </span></p>
<p style="top:251.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">285(1&#x2013;2):29&#x2013;39. doi:10.1016/j.heares.2012.01.013 </span></p>
<p style="top:261.3pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">43. Gunther M, Davidsson J, Plantman S, Norgren S, Mathiesen T, Risling M. </span></p>
<p style="top:270.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">Neuroprotective effects of N-acetylcysteine amide on experimental focal </span></p>
<p style="top:280.3pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">penetrating brain injury in rats. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Clin Neurosci</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2015) 22(9):1477&#x2013;83. </span></p>
<p style="top:289.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1016/j.jocn.2015.03.025 </span></p>
<p style="top:299.3pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">44. Haber M, Abdel Baki SG, Grin&#x2019;kina NM, Irizarry R, Ershova A, Orsi S, et&#xa0;al. </span></p>
<p style="top:308.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">Minocycline plus </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine synergize to modulate inflammation and </span></p>
<p style="top:318.3pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">prevent cognitive and memory deficits in a rat model of mild traumatic brain </span></p>
<p style="top:327.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">injury. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Exp Neurol</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2013) 249:169&#x2013;77. doi:10.1016/j.expneurol.2013.09.002 </span></p>
<p style="top:337.3pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">45. Hicdonmez T, Kanter M, Tiryaki M, Parsak T, Cobanoglu S. Neuroprotective </span></p>
<p style="top:346.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">effects of </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine on experimental closed head trauma in rats. </span></p>
<p style="top:356.3pt;left:320.2pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Neurochem Res</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2006) 31(4):473&#x2013;81. doi:10.1007/s11064-006-9040-z </span></p>
<p style="top:365.8pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">46. Kawoos U, McCarron RM, Chavko M. Protective effect of </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine </span></p>
<p style="top:375.3pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">amide on blast-induced increase in intracranial pressure in rats. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Front Neurol</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> </span></p>
<p style="top:384.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">(2017) 8:219. doi:10.3389/fneur.2017.00219 </span></p>
<p style="top:394.3pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">47. Naziroglu M, Senol N, Ghazizadeh V, Yuruker V. Neuroprotection induced </span></p>
<p style="top:403.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">by </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine and selenium against traumatic brain injury-induced </span></p>
<p style="top:413.3pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">apoptosis and calcium entry in hippocampus of rat. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Cell Mol Neurobiol</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2014) </span></p>
<p style="top:422.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">34(6):895&#x2013;903. doi:10.1007/s10571-014-0069-2 </span></p>
<p style="top:432.3pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">48. Pandya JD, Readnower RD, Patel SP, Yonutas HM, Pauly JR, Goldstein GA, </span></p>
<p style="top:441.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">et&#xa0;al. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine amide confers neuroprotection, improves bioenerget-</span></p>
<p style="top:451.3pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">ics and behavioral outcome following TBI. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Exp Neurol</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2014) 257:106&#x2013;13. </span></p>
<p style="top:460.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1016/j.expneurol.2014.04.020 </span></p>
<p style="top:470.3pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">49. Silva LF, Hoffmann MS, Rambo LM, Ribeiro LR, Lima FD, Furian AF, et&#xa0;al. </span></p>
<p style="top:479.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">The involvement of Na</span><span style="font-family:STIXGeneral,serif;font-size:7.5pt">+</span><span style="font-family:MinionPro,serif;font-size:7.5pt">, K</span><span style="font-family:STIXGeneral,serif;font-size:7.5pt">+</span><span style="font-family:MinionPro,serif;font-size:7.5pt">-ATPase activity and free radical generation in </span></p>
<p style="top:489.3pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">the susceptibility to pentylenetetrazol-induced seizures after experimental </span></p>
<p style="top:498.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">traumatic brain injury. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Neurol Sci</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2011) 308(1&#x2013;2):35&#x2013;40. doi:10.1016/j.</span></p>
<p style="top:508.3pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">jns.2011.06.030 </span></p>
<p style="top:517.8pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">50. Thomale UW, Griebenow M, Kroppenstedt SN, Unterberg AW, Stover JF. The </span></p>
<p style="top:527.3pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">antioxidant effect of </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N-</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">acethylcysteine on experimental contusion in rats. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Acta </span></i></p>
<p style="top:536.8pt;left:320.2pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Neurochir Suppl</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2005) 95:429&#x2013;31. doi:10.1007/3-211-32318-X_88 </span></p>
<p style="top:546.3pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">51. Thomale UW, Griebenow M, Kroppenstedt SN, Unterberg AW, Stover JF. </span></p>
<p style="top:555.8pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">The effect of </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine on posttraumatic changes after controlled </span></p>
<p style="top:565.4pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">cortical impact in rats. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Intensive Care Med</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2006) 32(1):149&#x2013;55. doi:10.1007/</span></p>
<p style="top:574.9pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">s00134-005-2845-4 </span></p>
<p style="top:584.4pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">52. Xiong Y, Peterson PL, Lee CP. Effect of N-acetylcysteine on mitochondrial </span></p>
<p style="top:593.9pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">function following traumatic brain injury in rats. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Neurotrauma</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (1999) </span></p>
<p style="top:603.4pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">16(11):1067&#x2013;82. doi:10.1089/neu.1999.16.1067 </span></p>
<p style="top:612.9pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">53. Xiong Y, Lin H, Chen BD, Peterson PL, Lee CP. Appearance of shortened Bcl-2 </span></p>
<p style="top:622.4pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">and Bax proteins and lack of evidence for apoptosis in rat forebrain after severe </span></p>
<p style="top:631.9pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">experimental traumatic brain injury. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Biochem Biophys Res Commun</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2001) </span></p>
<p style="top:641.4pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">286(2):401&#x2013;5. doi:10.1006/bbrc.2001.5396 </span></p>
<p style="top:650.9pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">54. Yi JH, Hazell AS. N-acetylcysteine attenuates early induction of heme oxy-</span></p>
<p style="top:660.4pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">genase-1 following traumatic brain injury. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Brain Res</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2005) 1033(1):13&#x2013;9. </span></p>
<p style="top:669.9pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1016/j.brainres.2004.10.055 </span></p>
<p style="top:679.4pt;left:306.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">55. Yi JH, Hoover R, McIntosh TK, Hazell AS. Early, transient increase in com-</span></p>
<p style="top:688.9pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">plexin I and complexin II in the cerebral cortex following traumatic brain </span></p>
<p style="top:698.4pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">injury is attenuated by </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Neurotrauma</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2006) 23(1):86&#x2013;96. </span></p>
<p style="top:707.9pt;left:320.2pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1089/neu.2006.23.86 </span></p>


<p style="top:741.9pt;left:292.4pt;line-height:7.0pt"><b><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">14</span></b></p>
<p style="top:28.6pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Bhatti et al.</span></p>
<p style="top:28.6pt;left:333.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Systematic Review on the Efficacy and Safety of </span><i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">N-</span></i><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Acetylcysteine in TBI</span></p>
<p style="top:741.9pt;left:45.4pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">Frontiers in Neurology | www.frontiersin.org</span></p>
<p style="top:741.9pt;left:432.0pt;line-height:7.0pt"><span style="font-family:Arial,serif;font-size:7.0pt;color:#6c6e70">January 2018 | Volume 8 | Article 744</span></p>
<p style="top:61.5pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">56. Abdel Baki SG, Kao HY, Kelemen E, Fenton AA, Bergold PJ. A hierarchy of </span></p>
<p style="top:71.0pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">neurobehavioral tasks discriminates between mild and moderate brain injury </span></p>
<p style="top:80.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">in rats. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Brain Res</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2009) 1280:98&#x2013;106. doi:10.1016/j.brainres.2009.05.034 </span></p>
<p style="top:90.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">57. Clausen F, Hanell A, Bjork M, Hillered L, Mir AK, Gram H, et&#xa0;al. Neutralization </span></p>
<p style="top:99.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">of interleukin-1beta modifies the inflammatory response and improves histo-</span></p>
<p style="top:109.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">logical and cognitive outcome following traumatic brain injury in mice. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Eur </span></i></p>
<p style="top:118.6pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Neurosci</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2009) 30(3):385&#x2013;96. doi:10.1111/j.1460-9568.2009.06820.x </span></p>
<p style="top:128.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">58. Powell D, Kaplan E, Whitla D, Weintraub S, Catlin R, Funkenstein H. </span></p>
<p style="top:137.6pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">MicroCog Assessment of Cognitive Functioning: Windows Edition</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">. San Antonio, </span></p>
<p style="top:147.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">TX: Pearson (2004).</span></p>
<p style="top:156.6pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">59. Ruff RM, Light RH, Parker SB, Levin HS. Benton controlled oral word </span></p>
<p style="top:166.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">association test: reliability and updated norms. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Arch Clin Neuropsychol</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (1996) </span></p>
<p style="top:175.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">11(4):329&#x2013;38. doi:10.1093/arclin/11.4.329 </span></p>
<p style="top:185.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">60. Agrawal Y, Carey JP, Hoffman HJ, Sklare DA, Schubert MC. The modified </span></p>
<p style="top:194.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">Romberg balance test: normative data in U.S. adults. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Otol Neurotol</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2011) </span></p>
<p style="top:204.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">32(8):1309&#x2013;11. doi:10.1097/MAO.0b013e31822e5bee </span></p>
<p style="top:213.6pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">61. Marchetti GF, Whitney SL, Blatt PJ, Morris LO, Vance JM. Temporal and </span></p>
<p style="top:223.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">spatial characteristics of gait during performance of the dynamic gait index </span></p>
<p style="top:232.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">in people with and people without balance or vestibular disorders. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Phys Ther</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> </span></p>
<p style="top:242.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">(2008) 88(5):640&#x2013;51. doi:10.2522/ptj.20070130 </span></p>
<p style="top:251.6pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">62. Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, </span></p>
<p style="top:261.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">et&#xa0; al. Nucleotide sequence of human monocyte interleukin 1 precursor </span></p>
<p style="top:270.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">cDNA. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Proc Natl Acad Sci U S A</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (1984) 81(24):7907&#x2013;11. doi:10.1073/</span></p>
<p style="top:280.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">pnas.81.24.7907 </span></p>
<p style="top:289.6pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">63. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfami-</span></p>
<p style="top:299.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">lies: integrating mammalian biology. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Cell</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2001) 104(4):487&#x2013;501. doi:10.1016/</span></p>
<p style="top:308.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">S0092-8674(01)00237-9 </span></p>
<p style="top:318.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">64. Risling M, Plantman S, Angeria M, Rostami E, Bellander BM, Kirkegaard M,  </span></p>
<p style="top:327.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">et&#xa0;al. Mechanisms of blast induced brain injuries, experimental studies in </span></p>
<p style="top:337.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">rats. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Neuroimage</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2011) 54(Suppl 1):S89&#x2013;97. doi:10.1016/j.neuroimage. </span></p>
<p style="top:346.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">2010.05.031 </span></p>
<p style="top:356.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">65. Uguz AC, Naziroglu M. Effects of selenium on calcium signaling and apopto-</span></p>
<p style="top:365.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">sis in rat dorsal root ganglion neurons induced by oxidative stress. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Neurochem </span></i></p>
<p style="top:375.1pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Res</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2012) 37(8):1631&#x2013;8. doi:10.1007/s11064-012-0758-5 </span></p>
<p style="top:384.6pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">66. Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and </span></p>
<p style="top:394.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">other methodological criteria of published animal studies: a systematic review. </span></p>
<p style="top:403.6pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Environ Health Perspect</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2013) 121(9):985&#x2013;92. doi:10.1289/ehp.1206389 </span></p>
<p style="top:413.1pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">67. Elbini Dhouib I, Jallouli M, Annabi A, Gharbi N, Elfazaa S, Lasram MM. A </span></p>
<p style="top:422.6pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">minireview on </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine: an old drug with new approaches. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Life Sci</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> </span></p>
<p style="top:432.1pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">(2016) 151:359&#x2013;63. doi:10.1016/j.lfs.2016.03.003 </span></p>
<p style="top:441.6pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">68. Rhodes K, Braakhuis A. Performance and side effects of supplementation with </span></p>
<p style="top:451.1pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine: a systematic review and meta-analysis. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Sports Med</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2017) </span></p>
<p style="top:460.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">47(8):1619&#x2013;36. doi:10.1007/s40279-017-0677-3 </span></p>
<p style="top:470.2pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">69. Skvarc DR, Dean OM, Byrne LK, Gray LJ, Ives K, Lane SE, et&#xa0;al. The post-an-</span></p>
<p style="top:479.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">aesthesia </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine cognitive evaluation (PANACEA) trial: study </span></p>
<p style="top:489.2pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">protocol for a randomised controlled trial. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Trials</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2016) 17:395. doi:10.1186/</span></p>
<p style="top:498.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">s13063-016-1529-4 </span></p>
<p style="top:508.2pt;left:45.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">70. Hammond CL, Marchan R, Krance SM, Ballatori N. Glutathione export during </span></p>
<p style="top:517.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">apoptosis requires functional multidrug resistance-associated proteins. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Biol </span></i></p>
<p style="top:527.2pt;left:59.4pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Chem</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2007) 282(19):14337&#x2013;47. doi:10.1074/jbc.M611019200 </span></p>
<p style="top:61.7pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">71. Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D. Antioxidant therapy </span></p>
<p style="top:71.2pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">in acute central nervous system injury: current state. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Pharmacol Rev</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2002) </span></p>
<p style="top:80.7pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">54(2):271&#x2013;84. doi:10.1124/pr.54.2.271 </span></p>
<p style="top:90.2pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">72. Bains M, Hall ED. Antioxidant therapies in traumatic brain and spinal </span></p>
<p style="top:99.7pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">cord injury. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Biochim Biophys Acta</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2012) 1822(5):675&#x2013;84. doi:10.1016/j.</span></p>
<p style="top:109.2pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">bbadis.2011.10.017 </span></p>
<p style="top:118.7pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">73. Adam-Vizi V, Chinopoulos C. Bioenergetics and the formation of mitochon-</span></p>
<p style="top:128.2pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">drial reactive oxygen species. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Trends Pharmacol Sci</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2006) 27(12):639&#x2013;45. </span></p>
<p style="top:137.7pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1016/j.tips.2006.10.005 </span></p>
<p style="top:147.2pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">74. Alali AS, Mukherjee K, McCredie VA, Golan E, Shah PS, Bardes JM, et&#xa0;al. </span></p>
<p style="top:156.7pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">Beta-blockers and traumatic brain injury: a systematic review, meta-analysis, </span></p>
<p style="top:166.2pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">and eastern association for the surgery of trauma guideline. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Ann Surg</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2017) </span></p>
<p style="top:175.7pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">266(6):952&#x2013;61. doi:10.1097/SLA.0000000000002286 </span></p>
<p style="top:185.2pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">75. Xiong Y, Mahmood A, Chopp M. Animal models of traumatic brain injury. </span></p>
<p style="top:194.7pt;left:320.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Nat Rev Neurosci</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2013) 14(2):128&#x2013;42. doi:10.1038/nrn3407 </span></p>
<p style="top:204.2pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">76. Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine for antiox-</span></p>
<p style="top:213.7pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">idant therapy: pharmacology and clinical utility. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Expert Opin Biol Ther</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2008) </span></p>
<p style="top:223.2pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">8(12):1955&#x2013;62. doi:10.1517/14728220802517901 </span></p>
<p style="top:232.7pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">77. Chavko M, Adeeb S, Ahlers ST, McCarron RM. Attenuation of pulmonary </span></p>
<p style="top:242.2pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">inflammation after exposure to blast overpressure by </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine amide. </span></p>
<p style="top:251.7pt;left:320.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Shock</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2009) 32(3):325&#x2013;31. doi:10.1097/SHK.0b013e31819c38f1 </span></p>
<p style="top:261.2pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">78. Rosenfeld CS. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">NACA for the Treatment of Chronic or Low Impact Brian </span></i></p>
<p style="top:270.7pt;left:320.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Trauma</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">. Google Patents US 2015112715 A1 (2015).</span></p>
<p style="top:280.2pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">79. Grinberg L, Fibach E, Amer J, Atlas D. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">N</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt">-acetylcysteine amide, a novel </span></p>
<p style="top:289.7pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">cell-permeating thiol, restores cellular glutathione and protects human red </span></p>
<p style="top:299.2pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">blood cells from oxidative stress. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Free Radic Biol Med</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2005) 38(1):136&#x2013;45. </span></p>
<p style="top:308.7pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">doi:10.1016/j.freeradbiomed.2004.09.025 </span></p>
<p style="top:318.2pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">80. Heidari K, Vafaee A, Rastekenari AM, Taghizadeh M, Shad EG, Eley R, et&#xa0;al. </span></p>
<p style="top:327.7pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">S100B protein as a screening tool for computed tomography findings after </span></p>
<p style="top:337.2pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">mild traumatic brain injury: systematic review and meta-analysis. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Brain Inj</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> </span></p>
<p style="top:346.7pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">(2015) 29(10):1&#x2013;12. doi:10.3109/02699052.2015.1037349 </span></p>
<p style="top:356.2pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">81. Yokobori S, Hosein K, Burks S, Sharma I, Gajavelli S, Bullock R. Biomarkers </span></p>
<p style="top:365.7pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">for the clinical differential diagnosis in traumatic brain injury &#x2013; a systematic </span></p>
<p style="top:375.2pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">review. </span><i><span style="font-family:MinionPro,serif;font-size:7.5pt">CNS Neurosci Ther</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (2013) 19(8):556&#x2013;65. doi:10.1111/cns.12127 </span></p>
<p style="top:384.8pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">82. Dixon CE, Kochanek PM, Yan HQ, Schiding JK, Griffith RG, Baum E, </span></p>
<p style="top:394.3pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">et&#xa0; al. One-year study of spatial memory performance, brain morphology, </span></p>
<p style="top:403.8pt;left:320.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">and cholinergic markers after moderate controlled cortical impact in rats. </span></p>
<p style="top:413.3pt;left:320.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">J Neurotrauma</span></i><span style="font-family:MinionPro,serif;font-size:7.5pt"> (1999) 16(2):109&#x2013;22. doi:10.1089/neu.1999.16.109 </span></p>
<p style="top:432.3pt;left:306.1pt;line-height:7.5pt"><b><span style="font-family:MinionPro,serif;font-size:7.5pt">Conflict of Interest Statement:</span></b><span style="font-family:MinionPro,serif;font-size:7.5pt"> The authors declare that the research was con-</span></p>
<p style="top:441.8pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">ducted in the absence of any commercial or financial relationships that could be </span></p>
<p style="top:451.3pt;left:306.1pt;line-height:7.5pt"><span style="font-family:MinionPro,serif;font-size:7.5pt">construed as a potential conflict of interest.</span></p>
<p style="top:470.3pt;left:306.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Copyright &#xa9; 2018 Bhatti, Nascimento, Akhtar, Rhind, Tien, Nathens and da Luz. </span></i></p>
<p style="top:479.8pt;left:306.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">This is an open-access article distributed under the terms of the Creative Commons </span></i></p>
<p style="top:489.3pt;left:306.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">Attribution License (CC BY). The use, distribution or reproduction in other forums </span></i></p>
<p style="top:498.8pt;left:306.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">is permitted, provided the original author(s) or licensor are credited and that the </span></i></p>
<p style="top:508.3pt;left:306.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">original publication in this journal is cited, in accordance with accepted academic </span></i></p>
<p style="top:517.8pt;left:306.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">practice. No use, distribution or reproduction is permitted which does not comply </span></i></p>
<p style="top:527.3pt;left:306.1pt;line-height:7.5pt"><i><span style="font-family:MinionPro,serif;font-size:7.5pt">with these terms.</span></i></p>

</div>
